0001387131-17-005495.txt : 20171114 0001387131-17-005495.hdr.sgml : 20171114 20171114103619 ACCESSION NUMBER: 0001387131-17-005495 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171114 DATE AS OF CHANGE: 20171114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vystar Corp CENTRAL INDEX KEY: 0001308027 STANDARD INDUSTRIAL CLASSIFICATION: FABRICATED RUBBER PRODUCTS, NEC [3060] IRS NUMBER: 202027731 STATE OF INCORPORATION: GA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53754 FILM NUMBER: 171199101 BUSINESS ADDRESS: STREET 1: 2484 BRIARCLIFF RD NE, #22, SUITE 159 CITY: ATLANTA STATE: GA ZIP: 30329 BUSINESS PHONE: 866-674-5238 MAIL ADDRESS: STREET 1: 2484 BRIARCLIFF RD NE, #22, SUITE 159 CITY: ATLANTA STATE: GA ZIP: 30329 10-Q 1 vyst-10q_093017.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________________to____________________

Commission File Number 000-53754

VYSTAR CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Georgia

20-2027731

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

2480 Briarcliff Rd, #6

Suite 159

Atlanta, GA 30329

(Address of Principal Executive Offices, Zip Code)

(866) 674-5238

(Registrant’s telephone number including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
(Do not check if a smaller reporting company)	Emerging growth company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) YES ☐ NO ☒

As of November 14, 2017, there were 132,189,001 shares of the Registrant’s common stock, par value $0.0001 per share, outstanding.

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

In addition to historical information, this Form 10-Q contains statements relating to our future results (including certain projections and business trends) that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are subject to the “safe harbor” created by those sections. The following discussion of the financial condition and results of operations of the Company should be read in conjunction with the financial statements and the related notes thereto included in this Quarterly Report on Form 10-Q (this “Report”). This Report contains certain forward-looking statements and the Company’s future operating results could differ materially from those discussed herein. Our disclosure and analysis included in this Report concerning our operations, cash flows and financial position, including, in particular, the likelihood of our success in expanding our business and raising debt and capital securities include forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expect”, “anticipate”, “intend”, “plan”, “believe”, “estimate”, “may”, “project”, “will likely result”, and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to certain risks, uncertainties, and assumptions, including prevailing market conditions and are more fully described under “Part I, Item 1A – Risk Factors” of our Form 10-K for the year ended December 31, 2016. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. In any event, these and other crucial factors, including those set forth in Item 1A – “Risk Factors” of our Form 10-K for the year ended December 31, 2016 may cause actual results to differ materially from those indicated by our forward-looking statements.

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s opinions only as of the date of this filing. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct or (iv) our strategy, which is based in part on this analysis, will be successful. The Company undertakes no obligation to update or revise forward-looking statements.

All references to “we”, “us”, “our”, “Vystar”, or “Kiron” in this Quarterly Report on Form 10-Q mean Vystar Corporation, and affiliates.

Vystar Corporation

Form 10-Q for the Quarter Ended September 30, 2017

Index

Part I. Financial Information

Item 1.	Financial Statements	3
	Balance Sheets at September 30, 2017 (unaudited) and December 31, 2016	3
	Statements of Operations for the Three Months and Nine Months Ended September 30, 2017 and 2016 (unaudited)	4
	Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 (unaudited)	5
	Notes to Financial Statements (unaudited)	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17

Item 4.	Controls and Procedures	17

Part II. Other Information

Item 1.	Legal Proceedings	17

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	17

Item 3.	Defaults Upon Senior Securities	18

Item 4.	Mine Safety Disclosures	18

Item 5.	Other Information	18

Item 6.	Exhibits	18

SIGNATURES		19

Part I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

VYSTAR CORPORATION

BALANCE SHEETS

	September 30,			December 31,
	2017			2016
ASSETS
CURRENT ASSETS
Cash	$	6,651		$	36,282
Accounts receivable, net of allowance for uncollectible amount of $0 at September 30, 2017 and December 31, 2016, respectively		5,440			17,370
Prepaid expenses		270,954			41,300
TOTAL CURRENT ASSETS		283,045			94,952
OTHER ASSETS
Intangible assets, net		127,802			139,562
TOTAL ASSETS	$	410,847		$	234,514
LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Related party line of credit	$	1,499,875		$	1,499,875
Accounts payable		394,824			488,784
Accrued compensation		—			2,917
Shareholder notes payable		591,529			595,837
Accrued expenses		339,946			231,080
TOTAL CURRENT LIABILITIES		2,826,174			2,818,493
Shareholder notes payable		198,461			239,231
TOTAL LIABILITIES	$	3,024,635		$	3,057,724
STOCKHOLDERS’ DEFICIT
Preferred stock, $0.0001 par value, 15,000,000 shares authorized; 13,828 issued and outstanding at September 30, 2017 and December 31, 2016 respectively		1			1
Common stock, $0.0001 par value, 250,000,000 shares authorized; 130,495,927 and 114,951,594 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively		13,050			11,495
Additional paid-in capital		25,060,524			23,979,943
Accumulated deficit		(27,687,363	)		(26,814,649	)
TOTAL STOCKHOLDERS’ DEFICIT		(2,613,788	)		(2,823,210	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	410,847		$	234,514

The accompanying notes are an integral part of these financial statements.

VYSTAR CORPORATION

STATEMENTS OF OPERATIONS

(unaudited)

	Three Months Ended June 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
REVENUE	$	5,400		$	29,642		$	11,723		$	37,264

COST OF REVENUE		4,775			3,000			15,800			15,973

Gross Margin		625			26,642			(4,077	)		21,291
OPERATING EXPENSES
General and administrative, including non-cash share-based compensation of $242,038 and $74,253 for the three months ended September 30, 2017 and 2016, respectively and $427,998 and $379,301 for the nine months ended September 30, 2017 and 2016, respectively		331,807			247,422			860,589			902,286

Total Operating Expenses		331,807			247,422			860,589			902,286

LOSS FROM OPERATIONS		(331,182	)		(220,780	)		(864,666	)		(880,995	)
OTHER INCOME (EXPENSE)

Interest income		—			—			—			1

Other income		78,513			(14,456	)		78,513			(14,456	)

Interest expense		(43,710	)		(40,125	)		(128,943	)		(134,233	)

Total Other Income (Expense)		34,803			(54,581	)		(50,430	)		(148,688	)

LOSS FROM CONTINUING OPERATIONS		(296,379	)		(275,361	)		(915,096	)		(1,029,683	)

INCOME (LOSS) FROM DISCONTINUED OPERATIONS		47,229			(31,030	)		42,382			43,207

NET LOSS	$	(249,150	)	$	(306,391	)	$	(872,714	)	$	(986,476	)
BASIC AND DILUTED LOSS PER SHARE:
Net loss per share	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.01	)
Basic and Diluted Weighted Average Number of Common Shares Outstanding		127,657,923			111,954,708			122,514,759			104,995,141

The accompanying notes are an integral part of these financial statements.

VYSTAR CORPORATION

STATEMENTS OF CASH FLOWS

(unaudited)

	Nine months ended September 30,
	2017			2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(872,714	)	$	(986,476	)
Adjustments to reconcile net loss to cash used in operating activities
Share-based compensation		427,998			379,301
Allowance for uncollectible accounts receivable		—			(60,266	)
Depreciation		—			278
Amortization of intangible assets		11,760			11,760
(Increase) decrease in assets
Accounts receivable		11,930			31,766
Prepaid expenses		(15,487	)		52,445
Increase (decrease) in liabilities
Accounts payable		(31,159	)		4,666
Accrued compensation and expenses		53,541			28,906
Net cash used in operating activities		(414,131	)		(537,620	)

CASH FLOWS FROM INVESTING ACTIVITIES
Disposal of equipment, net		—			2,701
Net cash provided by investing activities		—			2,701

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock, net of costs		384,500			570,000
Exercise of warrants/options		—			53,500
Net cash provided by financing activities		384,500			623,500

NET INCREASE (DECREASE) IN CASH		(29,631	)		88,581

CASH - BEGINNING OF YEAR		36,282			29,059

CASH - END OF PERIOD	$	6,651		$	117,640

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
NON-CASH TRANSACTIONS
Common stock issued for services to be rendered	$	214,167			—
Shareholder notes converted to common stock	$	55,470			—
CASH PAID DURING THE PERIOD FOR
Interest	$	73,875		$	96,176

The accompanying notes are an integral part of these financial statements.

VYSTAR CORPORATION

NOTES TO FINANCIAL STATEMENTS

NOTE 1

DESCRIPTION OF BUSINESS

Vystar Corporation (“Vystar”, the “Company”, “we”, “us”, or “our”) is the creator and exclusive owner of the innovative technology to produce Vytex® Natural Rubber Latex (“NRL”). Our global multi-patented technology reduces antigenic and total protein in natural rubber latex products to virtually undetectable levels. Vytex NRL, our “ultra-low protein” natural rubber latex has been introduced throughout the worldwide marketplace that uses NRL or latex substitutes as a raw material for end products. Natural rubber latex or latex substitutes are used in an extensive range of products including balloons, textiles, footwear and clothing (threads), adhesives, foams (mattresses, pillows, mattress toppers, etc.), furniture (foam and adhesives), carpet, paints, coatings, protective equipment, sporting equipment, and, especially health care products such as condoms, surgical and exam gloves, among others. Our challenge has been that a manufacturer’s conversion from the use of standard latex or synthetic raw material to Vytex NRL involves a protracted sales cycle ranging from eighteen to thirty-six months. Additionally, in the past, our primary method of distribution was via toll manufacturing. We now have several licensing agreements in place for global distribution that have allowed us to focus on and transition to sales and marketing with a technical oversight.

Vystar has expanded into the consumer arena with an introduction into the mattress, mattress topper and pillow arenas aligning with key foam manufacturers, mattress, mattress toppers and pillow producers, and furniture stores in specific areas of the Unites States. On January 22, 2015, Vystar announced the signing of an exclusive domestic distribution agreement with Worcester, MA based Nature’s Home Solutions (NHS) who sources eco-friendly materials and technologies for use in furnishings and other markets. In September 2016, the Vystar Board of Directors voted to end the January 2015 NHS agreement and replace it with a global exclusive for foam manufactured with Vytex and sold into the home furnishings industry. This change reflects the global nature of the mattress, topper and pillow businesses, the need for local warehousing, and access to container loads of foam cores and pillows for domestic, European and Asian manufacturers.

NOTE 2

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (“GAAP”) for interim financial information. Accordingly, certain information and footnotes required by GAAP for complete financial statements may be condensed or omitted. These interim financial statements should be read in conjunction with our audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission (“SEC”). In the opinion of Vystar management, these financial statements contain all adjustments (which comprise only normal and recurring accruals) necessary to present fairly the financial position and results of operations as of and for the three-month and nine-month periods ended September 30, 2017 and 2016.

Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future, actual results could differ from these estimates. Examples include valuation allowances for deferred tax assets, provisions for bad debts, and fair values of share-based compensation.

Concentration of Credit Risk

Certain financial instruments potentially subject the Company to concentrations of credit risk. These financial instruments consist primarily of cash and accounts receivable. Cash held in banks in many cases exceeds the Federal Deposit Insurance Corporation, or FDIC, insurance limits. While we monitor our cash balances on a regular basis and adjust the balances as appropriate, these balances could be impacted if the underlying financial institutions fail. To date, we have experienced no loss or lack of access to our cash; however, we can provide no assurances that access to our cash will not be impacted by adverse conditions in the financial markets.

Loss Per Share

Because the Company reported a net loss for the nine-month periods ended September 30, 2017 and 2016, common stock equivalents, including stock options and warrants, were anti-dilutive; therefore, the amounts reported for basic and diluted loss per share were the same. Excluded from the computation of diluted loss per share were options outstanding to purchase 8,298,271 shares and 9,718,271 shares of common stock for the nine months ended September 30, 2017 and 2016, respectively, as their effect would be anti-dilutive. Warrants to purchase 16,469,582 and 18,084,609 shares of common stock for the nine months ended September 30, 2017 and 2016, respectively, were also excluded from the computation of diluted loss per share as their effect would be anti-dilutive.

Revenues

The Company derives revenue from license fees of Vytex NRL raw material to manufacturers and distributors of rubber and rubber-end products such as the foam used in the pillows and mattresses. Revenue is recognized when the licensee confirms payment and pays Vystar.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash, accounts receivable, accounts payable, accrued expenses, line of credit and shareholder notes payable. The carrying values of all the Company’s financial instruments approximate fair value because of their short maturities. In addition to the short maturities, the carrying amounts of our line of credit and shareholder notes payable approximate fair value because the interest rates at September 30, 2017 approximate market interest rates for the respective borrowings.

In specific circumstances, certain assets and liabilities are reported or disclosed at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the Company’s principal market for such transactions. If there is not an established principal market, fair value is derived from the most advantageous market.

Valuation inputs are classified in the following hierarchy:

	●	Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
	●	Level 2 inputs are directly or indirectly observable valuation inputs for the asset or liability, excluding Level 1 inputs.
	●	Level 3 inputs are unobservable inputs for the asset or liability.

Highest priority is given to Level 1 inputs and the lowest priority to Level 3 inputs. Acceptable valuation techniques include the market approach, income approach, and cost approach. In some cases, more than one valuation technique is used.

NOTE 3

LIQUIDITY AND GOING CONCERN

The Company’s financial statements are prepared using the accrual method of accounting in accordance with GAAP and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. However, the Company has incurred significant losses and experienced negative cash flow since its inception. At September 30, 2017, the Company had cash of $6,651 and a deficit in working capital of $2,543,129. Further, at September 30, 2017, the accumulated deficit amounted to $27,687,363. As a result of the Company’s history of losses and financial condition, there is substantial doubt about the ability of the Company to continue as a going concern.

A successful transition to attaining profitable operations is dependent upon obtaining sufficient financing to fund the Company’s planned expenses and achieving a level of revenue adequate to support the Company’s cost structure. Management plans to finance future operations through the use of cash on hand, increased revenue from Vytex division license fees, our credit facility, stock warrant exercises from existing shareholders, raising capital through private placements of capital stock and debt.

The Company’s future expenditures will depend on numerous factors, including: the rate at which the Company can introduce and license Vytex NRL to manufacturers; the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; market acceptance of the Company’s products and services; revenue from the licensing agreement with NHS Holdings, LLC; and competing technological developments. As the Company expands its activities and operations, cash requirements are expected to increase at a rate consistent with revenue growth after the Company has achieved sustained revenue generation.

There can be no assurances that the Company will be able to achieve its projected level of revenue in 2017 and beyond. If the Company is unable to achieve its projected revenue and is not able to obtain alternate additional financing of equity or debt, the Company would need to significantly reorient its operations during 2017, which could have a material adverse effect on the Company’s ability to achieve its business objectives and as a result may require the Company to file for bankruptcy or cease operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

NOTE 4

DISCONTINUED OPERATIONS

As part of the Company’s strategy to focus on realizing the potential of the Vytex foam business in the pillow and mattress markets as well as part of the Company’s cost reduction plan, the Company made the decision in May 2016 to discontinue the operations of the Kiron division acquired in June 2013.

The Kiron division revenue was $0 and $4,538 for the three-month period ended September 30, 2017 and 2016, respectively and $130 and $80,988 for the nine-month period ended September 30, 2017 and 2016, respectively. Gains (Losses) from discontinued operations were $47,229 and ($31,030) for the three-month period ended September 30, 2017 and 2016, respectively and $42,382 and $43,207 for the nine-month period ended September 30, 2017 and 2016, respectively. These gains for the period were the result of the write-off of accounts payable associated with the previously closed SleepHealth and Kiron divisions.

NOTE 5

INTANGIBLE ASSETS

Patents represent legal and other fees associated with the registration of patents. The Company has four patents with the United States Patent and Trade Office (USPTO), as well as many international PCT (Patent Cooperation Treaty) patents.

Intangible assets are as follows:

	September 30, 2017			December 31, 2016

Patents	$	238,551		$	238,551
Trademarks & trade name		9,072			9,072
Subtotal		247,623			247,623
Accumulated amortization		(119,821	)		(108,061	)

Intangible assets, net	$	127,802		$	139,562

Amortization expense for the three months ended September 30, 2017 and 2016 was $3,920. Amortization expense for the nine months ended September 30, 2017 and 2016 was $11,760.

NOTE 6

INCOME TAXES

There is no income tax benefit recorded for the losses for the three and nine months ended September 30, 2017 and 2016 since management has determined that the realization of the net deferred tax asset is not assured and has created a valuation allowance for the entire amount of the net deferred tax asset.

NOTE 7

NOTES PAYABLE AND LOAN FACILITY

Related Party Line of Credit (CMA Note Payable)

On April 29, 2011, the Company executed with CMA Investments, LLC, a Georgia limited liability company (“CMA”), a line of credit with a principal amount of up to $800,000 (the “CMA Note”). CMA is a limited liability company of which three of the directors of the Company (“CMA directors”) were initially the members. Pursuant to the terms of the CMA Note, the Company may draw up to a maximum principal amount of $800,000. Interest, is computed at LIBOR plus 5.25% (6.50% at September 30, 2017), on amounts drawn and fees. The weighted average interest rate in effect on the borrowings for the six months ended September 30, 2017 was 5.25%.

Other terms of the CMA Note include:

●

The Note is unsecured;

●

No payments of principal are due until the second anniversary of the Note, at which time all outstanding principal is due and payable; and

●

As compensation to the directors for providing the Note, the Company issued warrants to purchase 2,600,000 shares of the Company’s common stock to the CMA Directors at $0.45 per share, which was the closing price of the Company’s stock on April 29, 2011, which vest 20% immediately and 10% upon each draw by the Company of $100,000 under the Note. Because the warrants were issued and valued prior to the receipt of funds under this loan, no discount could be recorded and, accordingly, the value of the warrants was capitalized as a financing cost. The costs are being amortized on a straight-line basis over the term of the Note.

On September 14, 2011, the Company’s Board of Directors approved increasing the line of credit with CMA by $200,000 to a maximum principal amount of $1,000,000 and the Company’s Chairman and Chief Executive Officer became a member of CMA. As compensation to the CMA Directors for increasing the amount available under the CMA Note, the Board of Directors approved modifying the exercise price for the 2,600,000 compensatory stock purchase warrants previously issued to the Directors from $0.45 to $0.27 per share, which was the closing price of the Company’s common stock on that date and the Company also issued warrants to purchase an additional 1,600,000 shares of the Company’s stock at $0.27 per share, which was the closing price of the Company’s common stock on September 14, 2011, which vest upon the original terms of the CMA Note. The costs incurred in the modification of the exercise price of the 2,600,000 compensatory stock purchase warrants issued on April 29, 2011 and the additional 1,600,000 warrants issued on September 14, 2011 are being amortized on a straight-line basis over the remaining term of the CMA Note.

On November 2, 2012, the Board of Directors approved an increase in the CMA line of credit from $1,000,000 to $1,500,000. As compensation to the CMA Directors for increasing the amount available under the CMA Note, warrants to purchase an additional 2,100,000 shares of the Company’s stock at $0.35 per share were issued and recorded as deferred financing cost to be amortized through interest expense over the remaining term of the CMA Note. There was no amortization of the financing costs associated with the CMA Note for the three and nine months ended September 30, 2017 and September 30, 2016.

On April 29, 2013, the maturity date of the CMA Note was extended to April 29, 2014. As compensation to the CMA Directors for extending the maturity date of the CMA Note, the Board of Directors approved modifying the exercise price for the 6,300,000 compensatory stock purchase warrants previously issued to the Directors to $0.10 per share and the CMA Directors forfeited 630,000 of the warrants. Amortization of the financing costs associated with extending the CMA Note was amortized through interest expense.

On April 30, 2014, the maturity date of the CMA Note was extended to April 30, 2015. No consideration was awarded the CMA members based on this extension.

On April 29, 2015, the maturity date of the CMA Note was extended to April 29, 2016. No consideration was awarded the CMA members based on this extension. The note is currently due on demand.

Shareholder Notes Payable

The following table summarizes the shareholder notes payable:

	September 30, 2017			December 31, 2016

Shareholder notes	$	789,990		$	835,068
Accrued Interest		276,146			231,080
Total Shareholder Notes & Accrued Interest		1,066,136			1,066,148

Less: Accrued Interest		(276,146	)		(231,080	)
Less: Current Portion		(591,529	)		(595,837	)
Total long-term debt	$	198,461		$	239,231

Such notes are (i) unsecured, (ii) bear interest at an annual rate ranging from five percent (5%) to ten percent (10%) per annum, and (iii) are convertible into shares of common stock at a conversion rate ranging between $0.05 and $0.10 of principal and interest for each such share.

The current average conversion price for the above referenced Shareholder and Promissory Notes with an outstanding balance as of September 30, 2017 of $1,066,136 including accrued interest, is approximately $0.055 per share or 19,305,727 shares of the Company’s common stock. The face value of the Shareholder Notes at September 30, 2017 is $789,990.

NOTE 8

STOCKHOLDERS’ EQUITY

Common Stock and Warrants

As part of the November 2016 Private Placement Memorandum, the Company issued 7,690,000 shares of common stock to sixteen (16) accredited investors during the period from January 1, 2017 to September 30, 2017. Total gross proceeds of the issuances were $384,500. No commissions were paid. The shares of common stock were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.

On March 15, 2017, the Company issued 400,000 common shares as compensation under the Company’s Business Development Agreement with FMW Media Works Corporation and 750,000 common shares as compensation under the Company’s Business Development Agreement with Joseph Savanyo.

On April 9, 2017, the Company issued 118,919 common shares as a result of a cashless exercise of outstanding warrants.

On April 25, 2017, the Company issued 1,109,406 common shares as a result of a partial conversion of a Shareholder Note and accrued interest.

On September 29, 2017, the Company issued 500,000 shares of common stock as part of the existing PPM to William Doyle, its CEO in lieu of salary earned in August and September 2017.

On September 27, 2017, the Company issued an additional 200,000 common shares as compensation under the Company’s Business Development Agreement with FMW Media Works Corporation and on July 30, 2017 200,000 common shares as compensation under the Company’s Business Development Agreement with Joseph Zampetti. On July 25, 2017 the Company issued 1,087,023 shares (dated June 29, 2017) to Blue Oar Consulting, Inc. as part of a prior contract.

On May 22, 2017, the Company signed a sales and marketing agreement with Anazca, LLC issuing restricted common shares quarterly and also as goals are achieved and issued 363,985 shares on September 28, 2017.

On July 1, 2017, the Company issued 3,125,000 shares to Accentuate Public Relations LLC under the Company’s Public Relations Services Agreement through December 2018.

Cumulative Convertible Preferred Stock

On May 2, 2013, the Company began a private placement offering to sell up to 200,000 shares of the Company’s 10% Series A Cumulative Convertible Preferred Stock. Under the terms of the offering, the Company offered to sell up to 200,000 shares of preferred stock at $10.00 per share for a value of $2,000,000. The preferred stock accumulates a 10% per annum dividend and was convertible at a conversion price of $0.075 per common share at the option of the holder after a nine-month holding period. The conversion price was lowered to $0.05 per common share for those holders who invested an additional $25,000 or more in the Company’s common stock in the aforementioned September 2014 Private Placement. The preferred shares have full voting rights as if converted and have a fully participating liquidation preference.

At September 30, 2017, the 13,828 shares of outstanding preferred stock had accumulated undeclared dividends of approximately $60,133, and could be converted into 3,968,269 shares of common stock, at the option of the holder.

NOTE 9

SHARE-BASED COMPENSATION

Generally accepted accounting principles require share-based payments to employees, including grants of employee stock options, warrants, and common stock to be recognized in the income statement based on their fair values at the date of grant, net of estimated forfeitures.

In total, the Company recorded $242,038 and $74,253 of stock-based compensation expense for the three-month period ended September 30, 2017 and 2016, respectively, and $427,998 and $379,301 of stock-based compensation expense for the nine-month period ended September 30, 2017, and 2016, respectively related to employee and board member stock options and common stock and warrants issued to nonemployees. As of September 30, 2017, $128,461 of unrecognized compensation expense related to non-vested share-based awards remains to be recognized over a period of approximately four years.

Options and Warrants

The Company used the Black-Scholes option pricing model to estimate the grant-date fair value of option and warrant awards granted. The following assumptions were used for warrant awards during the nine months ended September 30, 2017:

●

Expected Dividend Yield – because we do not currently pay dividends, the expected dividend yield is zero;

●

Expected Volatility in Stock Price – volatility based on our own trading activity was used to determine expected volatility;

●

Risk-free Interest Rate – reflects the average rate on a United States Treasury Bond with a maturity equal to the expected term of the option; and

●

Expected Life of Award – because we have minimal experience with the exercise of options or warrants for use in determining the expected life of each award, we used the option or warrant’s contractual term as the expected life.

Options

During 2004, the Board of Directors of the Company adopted a stock option plan (the “Plan”) and authorized up to 4,000,000 shares to be issued under the Plan. In April 2009, the Company’s Board of Directors authorized an increase in the number of shares to be issued under the Plan to 10,000,000 shares and to include the independent Board Members in the Plan in lieu of continuing the previous practice of granting warrants each quarter to independent Board Members for services. At September 30, 2017, there were 618,427 shares of common stock reserved for issuance under the Plan. In 2014, the Board adopted an additional stock option plan which provides for an additional 5,000,000 shares which are all available as of December 31, 2016. The Plan is intended to permit stock options granted to employees to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”). All options granted under the Plan that are not intended to qualify as Incentive Stock Options are deemed to be non-qualified options. Stock options are granted at an exercise price equal to the fair market value of the Company’s common stock on the date of grant, typically vest over periods up to 4 years and are typically exercisable up to 10 years.

There were no options granted during the nine-month period ended September 30, 2017. The following table summarizes all stock option activity of the Company for the period.

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)

Outstanding, December 31, 2016		9,418,271	$	0.16		4.43

Granted		—

Exercised		—

Expired		1,120,000

Outstanding, September 30, 2017		8,298,271	$	0.16		4.10

Exercisable, September 30, 2017		6,533,271	$	0.20		5.29

Warrants

Warrants are issued to employees for expenses and for compensation in lieu of cash as well as to third parties as payment for services and in conjunction with the issuance of common stock. The fair value of each common stock warrant issued for services is estimated on the date of grant using the Black-Scholes option pricing model.

The weighted-average assumptions used in the option pricing model for stock warrant grants were as follows:

	2017
Expected Dividend Yield	0.00	%
Expected Volatility in Stock Price	150.82	%
Risk-Free Interest Rate	1.99	%
Expected Life of Stock Awards – Years	6.86

The following table represents the Company’s warrant activity for the nine months ended September 30, 2017:

	Number of Shares			Weighted Average Grant Date Fair Value		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)

Outstanding, December 31, 2016		16,122,332				$	0.10		6.10

Granted		1,240,250		$	0.14	$	0.14		6.39

Exercised		(200,000	)			$	0.05

Forfeited		(693,000	)			$	0.14

Expired		—

Outstanding, September 30, 2017		16,469,582				$	0.10		5.04

Exercisable, September 30, 2017		16,173,221				$	0.10		5.36

The Company issued 1,240,250 warrants for services during the nine months ended September 30, 2017 at exercise prices from $0.07 to $0.17 per share, exercisable over a period of five to ten years from the grant date. All of the warrants with the exception of 362,219 vested immediately with the 362,219 warrants vesting one-eleventh per month over an eleven-month period. The total amount of the fair value of this grant was $50,000 and is recorded as noncash share-based compensation expense as vesting occurs. The fair value of the warrants was calculated as of the date of the grant utilizing the Black-Scholes option pricing model and assumptions as detailed above.

NOTE 10

SUBSEQUENT EVENTS

On October 9, 2017, the Company issued 481,884 common shares as a result of a cashless exercise of outstanding warrants.

On October 10, 2017, the Company issued Shareholder Notes for a total of $45,000.

On October 20, 2017, the Company issued Anazca 368,217 shares as a quarterly commitment. Anazca, LLC subsequently resigned from their contract effective November 3, 2017.

On November 6, 2017, the Company issued 250,000 shares of common stock as part of the existing PPM to William Doyle, its CEO in lieu of salary earned during October 2017.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

Natural rubber latex is an agricultural product produced from the sap of the rubber tree, Hevea brasiliensis. According to the most recent data available and obtained on the International Rubber Study Group web site (www.rubberstudy.com) and dated January 6, 2015: the total world rubber demand increased at 1.8% and 4.1% in 2015 and 2016 respectively, growing below the long-term growth rate of 3.7% under the IMF Scenario to 29.1 million tonnes in 2015 and to 30.3 million tonnes in 2016.

World Natural Rubber (NR) demand increased by 3.1% in 2015 under the IMF Scenario and by 4.4% in 2016. The world total NR consumption was 12.3 million tonnes in 2015, 12.9 million tonnes in 2016 and is expected to increase to 16.5 million tonnes in 2023. World Synthetic Rubber (SR) demand was 16.8 million tonnes in 2015 and 17.5 million tonnes in 2016 under the IMF Scenario. In 2023, the demand for SR will be 21.5 million tonnes. The outlook for NR supply is positive, sufficient to meet the demand of the industry for all forecast years under all three scenarios. Almost 60% of global consumption is by the world’s tire manufacturing industry, with the remainder going into the ‘general rubber products’ sector; many thousands of different goods are manufactured by this sector, serving many industries, including transport, construction, health, mining, apparel, foam, etc.

Substantially all of the latex processors are located in Southeast Asia, India, Africa and Latin America and are owned by local groups or large multinational corporations. This future demand is awakening interest in other areas of the world where the climate is suitable, particularly in Guatemala, where focus now shifts to certifications from the Forestry Stewardship Council and Rainforest Alliance, as a specialty latex. In addition to the resurgence of Central and South America in natural rubber latex production, countries such as Vietnam and Cambodia have launched major efforts to meet the needs of the global liquid natural rubber latex market. Vietnam is now a major processor of our Vytex NRL and several trial runs of the specialty offerings discussed below that are in place for manufacturer trials and we now have two producers in Guatemala, one starting the trial phase.

Our initial product portfolio included Vytex NRL in high ammonia (HA) and low ammonia (LA) formulations. New specialized formulations are projected to come to market over the next year with trials in ultra-low ammonia, pre-vulcanized and low nitrosamine versions currently taking place. Vystar has used its technology to work with customers to solve production issues and provide them with a point of difference and guidance as research using Vytex has headed into directions previously thought to be off-limits to natural rubber latex. It appears to be the removal of the vast majority of the proteins, the carotenoids and the non-rubbers that affords Vytex NRL this opportunity.

Board of Directors Member and Research & Development Director Ranjit K. Matthan, Ph.D., revealed ongoing developments in the formulation of Vytex NRL with reduced or no ammonia and nitrosamines at the International Latex Conference (ILC) session titled “Advances in Environmentally Friendly Ultra Low Protein Natural Rubber Specialty Latices” on August 12, 2015. The significant advances in aluminum hydroxide-treated Vytex NRL properties and applications are potential game-changers for the issues of volatile organic content and nitrosamines for some critical latex products, such as balloons, catheters, condoms, and other medical devices, as well as enabling cleaner and more sustainable work environments. The expanded Vystar product grades make it applicable in a wider range of latex products with the advantage of improved environmental impact through reduced leachables/extractables. The advances deliver a simplified, sustainable, totally safe raw material that Vystar can offer for several applications without reservations about nitrosamines. Production scale up of all three newer versions of Vytex NRL is currently being targeted as well as sample fulfillment.

Recently at the 2017 Nuremberg Toy Show (Speilwarenmesse) Vytex NRL was a targeted product for manufacturers of balloons, masks, etc. On the main page of the European Balloons and Party Council web site is a Yahoo video still plus a recent press release that discusses the benefits of Vytex NRL in items such as balloons. As there is a new proposal for limits on protein content of balloons by virtue of an EN listing, Vytex has now gone in to full pre-vulcanized testing to start the sampling process in this very large European manufacturing market (Italy, Austria, Spain, etc.) for balloons and has already spread to areas in Central and South America.

Over the course of several years, our technical groups have presented technical papers of varying topics that still hold relevance. Vytex NRL is produced at the latex processor level and can be integrated into the current processing environments without additional capital equipment investment. The protein removal and modification process that leads to Vytex NRL allows manufacturers to lower manufacturing costs with the benefit of reduced protein levels. Reduced leaching times and resulting reductions in energy, water and material handling consumption can lead to realized cost savings.

Also, “Eco-Friendly Manufacturing of High Performance Latex using Ultra Low Antigenic Protein Latex” reviewed some of the learnings Vystar had made since commercializing Vytex NRL. Among these discoveries were: improved air and helium retention in balloons; reduced leaching needs for some dipped products; truer colors for dyed dipped products (such as balloons); and low latex odor in foams, which has now led to unique research into areas previously considered off-limits to NRL. Vystar published and presented a paper, “Further Development of Vytex® Natural Rubber Latex Leads to Strong Niche Market Advances”, that added additional learnings related to slow release (memory) foam formulations and other technical improvements helping customers solve their new product development challenges.

Vystar has transitioned from toll manufacturing agreements to licensing agreements that eliminate the need to maintain a costly infrastructure along with the other investment and regulatory compliance costs to develop and operate a processing or manufacturing facility. All of these costs are or will be borne by our manufacturing and distribution contractors and/or customers. This means we must show the NRL producers and product manufacturers the economic value proposition of including Vytex NRL in their product lines, hence the technical paper presentations we have made and continue to make. In addition, as an all-natural raw material, Vytex NRL puts the main component in gloves and other products back in the environmentally friendly arena.

Increased interest in the exam glove arena has put Vystar in the enviable position of needing glove manufacturers to work with to handle the expected transition of healthcare companies, clinics and non-medical uses. Vystar is currently working with an American manufacturing facility to handle some of these needs as they prepare for production start-up. Other glove manufacturers are also being sought.

To implement our licensing model, in March 2010 we signed a licensing agreement with Pica de Hule Natural, a division of Grupo Agroindustrial de Occidente (“Occidente”), located in Guatemala. Occidente is the largest processor of natural rubber latex in Latin America and the largest exporter serving more than 15 countries. Under the agreement, Occidente will manufacture, sell and market Vytex NRL throughout Latin America as well as supply Vytex NRL to North America and Europe. This agreement was continued in 2016 for an additional 5 years

In October 2010, we signed a second licensing agreement with KA Prevulcanized Latex (KAPVL) to manufacture and sell Vytex NRL in the SAARC region which includes India, Pakistan, Sri Lanka, Bangladesh, Bhutan and Nepal. India is the second largest consumer of concentrated latex behind China. In 2014, this agreement ended and we did not renew.

In addition, in January 2009, we entered into a Distribution Agreement with Centrotrade Minerals & Metals, US and Centrotrade Deutschland, GmbH, Germany, a leading global distributor of latex raw materials, to create a worldwide distribution network that will further enhance our ability to cost effectively reach and service manufacturer customers in these key manufacturing areas. This provides an expansive distribution network that facilitates both the licensing and toll manufacturing models and can assist with various processors in taking their products to market. On December 19, 2012, we amended our agreement with Centrotrade to expand Vytex NRL distribution rights to the world’s largest NRL consuming markets in Southeast Asia, specifically Malaysia and Thailand. Under this new license agreement, Centrotrade controls production scheduling of Vytex NRL, inventory in Thailand, sales, pricing and customer financing, while Vystar will focus on marketing, customized product development, as noted above, and support activities. Vystar currently has no exclusive areas under contract as RCMA, a Dutch based distributor was added in 2016.

The paper entitled, “The Non-Enzymatic Deproteinization of Natural Rubber Latex (DPNRL) Enabling the Greater Versatility in End Product Applications” discussed improvements that extend beyond the ultra-low allergenicity of the DPNRL and include improved color, absence of rubber odor, and improved physicochemical attributes. Improved air and helium retentions results were reported. The potential to extend applications into other non-conventional areas other than latex end products was discussed and we are currently in the retail test market stages for the United States based manufacturing of mattresses, pillows and toppers to key furniture stores and buying groups, primarily in the Northeastern United States and signed a 5-year renewable agreement in January 2015 with Nature’s Home Solutions (NHS) to exclusively distribute these products in the United States. In September 2016, the Vystar Board of Directors voted to end the January 2015 NHS agreement and replace it with a global exclusive for foam manufactured with Vytex and sold into the home furnishings industry. This change reflects the global nature of the mattress, topper and pillow businesses, the need for local warehousing, and access to container loads of foam cores and pillows for domestic, European and Asian manufacturers.

Samples have been presented to the manufacturers and feedback has been very positive with names such as Gold Bond, King Coil (Natura and Laura Ashley) and SpringAir (Nature’s Rest) adding Vytex to their current offerings. A similar trial occurred in October 2016 in Thailand focusing on specific densities and pillows, and a meeting with a Belgian foam maker using a unique drying concept occurred in May 2016 with discussions ongoing. In addition, working with NHS and a large Vietnamese foam manufacturer, Lien A, the group attended the International Sleep Products Association (ISPA) in Orlando in March 2016 a select group attended the ISPA technical show in March 2017 in Tampa. The significance of ISPA is the focus on components for use with major mattress and pillow manufacturers, which takes Vytex foam to an additional audience. NHS sees steady increased exponential growth throughout the remainder of 2017 and the companies, combined with Lien A, have structured the needed supply chain.

Pricing of materials in the rubber and latex industries continues to fluctuate. Prices of centrifuged latex, thus Vytex, have risen throughout 2016 and in to early 2017 due to various factors such as floods in southern Thailand, removal of older tress and replanting which is a seven-year process, newer plantations coming online, etc.

Working through distribution with global manufacturers, Vystar secured a commitment from a major manufacturer of dielectric gloves qualifying Vytex to run on a full production line with potential to move to other lines and more of their international locations. Licensing discussions began in November 2016 and has now expanded to full container shipments with additional manufacturing plants set to come on throughout 2017. We are also expanding our usage of Vytex with a worldwide manufacturer of cold seal adhesives to complement the current business in sports shoes and starting a re-trial with a large domestic adhesive company in second quarter 2017.

With the introduction of several new versions of Vytex at the ILC meeting mid-2015, we secured several trials with toy manufacturers arena who desire the lowest levels of nitrosamine and protein per European standards. This affects European balloon manufacturers as well as those selling balloons in the European markets. Also, as an alternative raw material has ceased production, a catheter manufacturer is now trialing Vytex for their internal balloons with results now being evaluated. Vystar has also progressed well in pilot line trials with a major women’s apparel retailer

A small trial is commencing with a start-up American manufacturer of exam gloves, using Vytex, as requested by a major outpatient provider of services. The dipping process for the exam gloves will progress in the next months to provide samples for early evaluation with center-wide trials to start upon approval. As the USFDA 510k allowance for an exam glove containing Vytex is for an un-powdered glove, we are well positioned to manage expectations for those requiring an exam glove without powder with a lower antigenic protein content with two trials currently in place.

RESULTS OF OPERATIONS

Comparison of the Three Months Ended September 30, 2017 with the Three Months Ended September 30, 2016

	Three Months Ended September 30,																		Continuing						Consolidated
	2017									2016									$ change			% change			$ change			% change
	Continuing			Discontinued			Consolidated			Continuing			Discontinued			Consolidated
Revenue, net	$	5,400		$	—		$	5,400		$	29,642		$	4,538		$	34,180		$	(24,242	)		(81.8	%)	$	(28,780	)		(84.2	%)
Cost of revenue		4,775			—			4,775			3,000			(18,716	)		(15,716	)		1,775			59.2	%		20,491			(130.3	%)
Gross profit/(loss)		625			—			625			26,642			23,254			49,896			(26,017	)		(97.7	%)		(49,271	)		(98.7	%)

Operating Expenses
General and administrative		331,807			1,789			333,596			247,422			51,583			299,005			84,385			34.1	%		34,591			11.6	%
Total operating expenses		331,807			1,789			333,596			247,422			51,583			299,005			84,385			34.1	%		34,591			11.6	%

Profit (Loss) from Operations		(331,182	)		(1,789	)		(332,971	)		(220,780	)		(28,329	)		(249,109	)		(110,402	)		(50.0	%)		(83,862	)		(33.7	%)

Other income/(expense)		78,513			49,018			127,532			(14,456	)		(2,701	)		(17,157	)		92,969			(643.1	%)		144,689			(843.3	%)
Interest expense		(43,710	)		—			(43,710	)		(40,125	)		—			(40,125	)		(3,585	)		8.9	%		(3,585	)		8.9	%
Total Other Income/Expense		34,804			49,018			83,822			(54,581	)		(2,701	)		(57,282	)		89,385			(163.8	%)		141,104			(246.3	%)

Net loss	$	(296,378	)	$	47,229		$	(249,149	)	$	(275,361	)	$	(31,030	)	$	(306,391	)	$	(21,017	)		(7.6	%)	$	57,242			18.7	%

Revenues

Revenues for the three months ended September 30, 2017 and 2016 from the Company were $5,400 and $34,180, respectively, for a decrease of $28,780 or 84.2%. The decrease in revenues from operations was due to a significant drop in Vytex royalty revenue and the elimination of the Kiron division. Revenues for the three months ended September 30, 2017 and 2016 from the Company’s continuing operations were $5,400 and $29,642, respectively, for a decrease of $24,242 or 81.8%. The decrease in revenues from continuing operations was due to a drop in Vytex sales and yet to be realized Vytex foam royalties.

For the Company, gross margin fell from $49,896 for the period ended September 30, 2016 to $625 for the period ended September 30, 2017, a decrease of $49,271 or 98.7%. Gross margin from continuing operations for the three months ended September 30, 2017 and 2016 was $625 and $26,642 respectively, for a decrease of $26,017 or 97.7%. Cost of revenue from continuing operations for the three months ended September 30, 2017 and 2016 was $4,775 and $3,000 respectively an increase of $1,775 or 59.2%. This was a result of additional shipping costs and Vytex testing expense.

Operating Expenses

The Company’s operating expenses consist of general and administrative expenses. General and administrative expenses consist primarily of compensation and support costs for management and administrative staff, and for other general and administrative costs, including professional fees related to accounting, finance, and legal services as well as other operating expenses. The Company’s operating expenses were $333,596 and $299,005 for the three months ended September 30, 2017 and 2016, respectively, for an increase of $34,591 or 11.6%. This was primarily the result of an increase in third-party contracted expenses offset by the closing of the Kiron division. The Company’s operating expenses from continuing operations were $331,807 and $247,422 for the three months ended September 30, 2017 and 2016, respectively, for an increase of $84,385 or 34.1%. This was the result of an increase in third-party contracted expenses.

Other Income (Expense)

Other income (expense) for the three months ended September 30, 2017 consisted of interest expense of $43,710 and other income of $127,532. This compares to net interest expense of $40,125 and other expense of $17,157 for the three months ended September 30, 2016. The increase in interest expense for the quarter ended September 30, 2017 versus the same quarter in 2016 was primarily attributable to an increase in LIBOR. Other income for the period was the result of derecognition and write-off of accounts payable associated with the previously closed SleepHealth and Kiron divisions.

Net Loss

Net loss was $249,149 and $306,391 for the three months ended September 30, 2017 and 2016, respectively, a decrease of $57,242 or 18.7% in the net loss. The smaller net loss the Company experienced in the quarter ended September 30, 2017 versus the same period in 2016 was primarily attributable to the derecognition and write-off of accounts payable with the previously closed SleepHealth and Kiron divisions.

Comparison of the Nine Months Ended September 30, 2017 with the Nine Months Ended September 30, 2016

	Nine Months Ended September 30,																		Continuing						Consolidated
	2017									2016									$ change			% change			$ change			% change
	Continuing			Discontinued			Consolidated			Continuing			Discontinued			Consolidated
Revenue, net	$	11,723		$	130		$	11,853		$	37,264		$	80,988		$	118,252		$	(25,541	)		(68.5	%)	$	(106,399	)		(90.0	%)
Cost of revenue		15,800			20			15,820			15,973			15,144			31,117			(173	)		(1.1	%)		(15,297	)		49.2	%
Gross profit		(4,077	)		110			(3,967	)		21,291			65,844			87,135			(25,368	)		(119.1	%)		(91,102	)		(104.6	%)

Operating Expenses
General and administrative		860,589			7,741			868,330			902,286			22,531			924,817			(41,697	)		(4.6	%)		(56,487	)		(6.1	%)
Total operating expenses		860,589			7,741			868,330			902,286			22,531			924,817			(41,697	)		(4.6	%)		(56,487	)		(6.1	%)

Profit (Loss) from Operations		(864,666	)		(7,631	)		(872,297	)		(880,995	)		43,313			(837,682	)		16,329			1.9	%		(34,615	)		(4.1	%)

Other income/(expense)		78,513			50,051			128,564			(14,455	)		(2,700	)		(17,155	)		92,968			(643.1	%)		145,719			(849.3	%)
Interest expense		(128,943	)		(38	)		(128,981	)		(134,233	)		2,594			(131,639	)		5,290			(3.9	%)		2,658			(2.0	%)
Total Other Income/Expense		(50,430	)		50,013			(417	)		(148,688	)		(106	)		(148,794	)		98,258			66.1	%		148,377			99.7	%

Net Income/(Loss)	$	(915,096	)	$	42,382		$	(872,714	)	$	(1,029,683	)	$	43,207		$	(986,476	)	$	114,587			11.1	%	$	113,762			11.5	%

Revenues

Revenues for the nine months ended September 30, 2017 and 2016 from the Company were $11,853 and $118,252 respectively, for a decrease of $106,399 or 90.0%. The decrease in revenues from operations was due to the closing of Kiron and a fall in Vytex royalty revenue. Revenues for the nine months ended September 30, 2017 and 2016 from the Company’s continuing operations were $11,723 and $37,264 respectively, for a decrease of $25,541 or 68.5%. The decrease in revenues from continuing operations was due to the drop in raw latex prices and the resultant drop in Vytex licensing fee. The Company has also not yet been able to realize royalties from Vytex foam sales.

For the Company, gross margin fell from $87,135 for the period ended September 30, 2016 to a gross loss of $3,967 for the period ended September 30, 2017, a decrease of $91,102 or 104.6%. Gross margin from continuing operations for the nine months ended September 30, 2017 and 2016 was ($4,077) and $21,291 respectively, for a decrease of $25,368 or 119.1%. Cost of revenue from continuing operations for the nine months ended September 30, 2017 and 2016 was $15,800 and $15,973 respectively, a decrease of $173 or 1.1%.

Operating Expenses

The Company’s operating expenses consist of general and administrative expenses. General and administrative expenses consist primarily of compensation and support costs for management and administrative staff, and for other general and administrative costs, including professional fees related to accounting, finance, and legal services as well as other operating expenses. The Company’s operating expenses were $865, 330 and $924, 817 for the nine months ended September 30, 2017 and 2016, respectively, for a decrease of $56,487 or 6.1%. This was primarily the result of the closing of the Kiron division and a reduction in third-party contracted services. The Company’s operating expenses from continuing operations were $860,589 and $902,286 for the nine months ended September 30, 2017 and 2016, respectively, for a decrease of $41,697 or 4.6%.

Other Income (Expense)

Other income (expense) for the nine months ended September 30, 2017 consisted of interest expense of $128,981 and other income of $128,564. This compares to interest expense of $131,639 for the nine months ended September 30, 2016 and other expense of $17,155. The decrease in interest expense for the period ended September 30, 2017 versus the same period in 2016 was attributable to a decrease in interest expense associated with outstanding Shareholder Notes. Other income for the period was the result of derecognition and write-off of accounts payable associated with the previously closed SleepHealth and Kiron divisions.

Net Loss

Net loss was $872,714 and $986,476 for the nine months ended September 30, 2017 and 2016, respectively, a decrease of $113,762 or 11.5% in the net loss. The smaller net loss the Company experienced in the period ended September 30, 2017 versus the same period in 2016 was primarily a reduction in third-party contract services the result of derecognition and the write-off of accounts payable associated with the previously closed SleepHealth and Kiron divisions.

LIQUIDITY AND CAPITAL RESOURCES

The Company’s future expenditures will depend on numerous factors, including: the rate at which the Company can introduce and license Vytex NRL to manufacturers; the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; market acceptance of the Company’s products and services; and competing technological developments. As the Company expands its activities and operations, cash requirements are expected to increase at a rate consistent with revenue growth after the Company has achieved sustained revenue generation.

Sources and Uses of Cash

For the nine months ended September 30, 2017 and 2016, net cash used in operations was $414,131 and $537,620 respectively. The negative cash flow for the nine months ended September 30, 2017 resulted primarily from the net loss of $872,714, offset by non-cash charges related to non-cash share-based compensation expense of $427,998, and a decrease in accounts receivable of $11,930, and an increase in accrued expenses of $53,541. The negative cash flow for the nine months ended September 30, 2016 resulted primarily from the net loss of $986,476 and a decrease in allowance for uncollectible accounts receivable of $60,266 offset by non-cash charges related to non-cash share-based compensation expense of $379,301, prepaid expenses of $52,445, accounts receivable of $31,766 and accrued expenses of $28,906.

For the nine months ended September 30, 2017 the Company had no investing activity. For the nine months ended September 30, 2016 the Company realized $2,701 from the disposal of equipment from the closing of the Kiron division.

Net cash provided by financing activities for the nine months ended September 30, 2017 was $384,500 from the sale of common stock. Net cash provided by financing activities for the nine months ended September 30, 2016 was $570,000 in proceeds from the sale of common stock and $53,500 from the exercise of warrants.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that may be reasonably likely to have a current or future material effect on our financial condition, liquidity, or results of operations.

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

Our Management’s Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth; product development, introduction and acceptance; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission.

Although the forward-looking statements in this Quarterly Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

None

ITEM 4. CONTROLS AND PROCEDURES

(A) Evaluation of disclosure controls and procedures

Our management, including our principal executive and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2017. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this quarterly report on Form 10-Q has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures are effective to the reasonable assurance level.

(B) Changes in internal control over financial reporting

We regularly review our system of internal control over financial reporting and make changes to our processes and systems to improve controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include such activities as implementing new, more efficient systems, consolidating activities, and migrating processes.

There were no changes in our internal control over financial reporting that occurred during the first nine months of 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Set forth below is information regarding shares of common stock, warrants and options to purchase common stock issued by the Company for the nine months ended September 30, 2017, that were not registered under the Securities Act of 1933, as amended (the “Securities Act”). Also included is the consideration, if any, received by the Company for such shares, warrants and options and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed.

(a) Common Stock Financings

From December 31, 2016 through September 30, 2017, the Company issued 7,690,000 shares of common stock at $0.05 per share for $384,500. The Company also issued 118,919 shares of common stock as a result of a non-cash warrant exercise and 1,109,406 shares of common stock as a result of a shareholder note and accrued interest conversion.

(b) Stock Option Grants

From December 31, 2016 through September 30, 2017, the Company did not grant any stock options.

(c) Application of Securities Laws and Other Matters

No underwriters were involved in the foregoing sales of securities. The securities described in section (a) of this Item 2 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(2) under the Securities Act and Regulation D promulgated thereunder, as applicable, relative to sales by an issuer not involving any public offering, to the extent an exemption from such registration was required.

All of the foregoing securities are deemed restricted securities for purposes of the Securities Act. All certificates representing the issued shares of common stock, warrants and options described in this Item 2 included appropriate legends setting forth that the securities had not been registered and the applicable restrictions on transfer.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

Exhibit Index

Number		Description

31.1 *		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 *		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 *		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	VYSTAR CORPORATION

Date: November 14, 2017	By:	/s/ William R. Doyle
		William R. Doyle
		President, Chief Executive Officer, Chief Financial Officer and Director

EX-31.1 2 ex31-1.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

Vystar Corporation 10-Q

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, William R. Doyle, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Vystar Corporation (the “Company”) for the quarter ended September 30, 2017

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and I have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision to ensure that material information relating to the Company is made known to me by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: November 14, 2017	By:	/s/ William R. Doyle
		President, Chief Executive Officer, Chief Financial Officer and Director

EX-31.2 3 ex31-2.htm CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

Vystar Corporation 10-Q

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, William R. Doyle, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Vystar Corporation (the “Company”) for the quarter ended September 30, 2017

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: November 14, 2017	By:	/s/ William R. Doyle
		President, Chief Executive Officer, Chief Financial Officer and Director

EX-32.1 4 ex32-1.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

Vystar Corporation 10-Q

Exhibit 32.1

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Vystar Corporation (the “Company”) on Form 10-Q for the Quarter Ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, William R. Doyle, President and Chief Executive Officer of the Company, and interim Chief Financial Officer of the Company, does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ William R. Doyle
William R. Doyle
President, Chief Executive Officer, Chief Financial Officer and Director

A signed original of this written statement required by Section 906 has been provided to Vystar Corporation and will be retained by Vystar Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of Vystar Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

EX-101.INS 5 vyst-20170930.xml XBRL INSTANCE DOCUMENT 0001308027 2017-09-30 0001308027 2016-12-31 0001308027 2017-01-01 2017-09-30 0001308027 us-gaap:StockOptionMember 2016-01-01 2016-09-30 0001308027 us-gaap:StockOptionMember 2017-01-01 2017-09-30 0001308027 vyst:Warrant1Member 2016-01-01 2016-09-30 0001308027 vyst:Warrant1Member 2017-01-01 2017-09-30 0001308027 us-gaap:StockCompensationPlanMember 2009-04-30 0001308027 vyst:CmaNoteMember 2011-04-29 0001308027 vyst:CmaNoteMember 2011-09-13 2011-09-14 0001308027 vyst:CmaNoteMember 2011-09-14 0001308027 vyst:CmaNoteMember 2012-11-02 0001308027 vyst:CmaNoteMember us-gaap:WarrantMember 2011-04-28 2011-04-29 0001308027 vyst:CmaNoteMember us-gaap:WarrantMember 2011-04-29 0001308027 vyst:CmaNoteMember us-gaap:WarrantMember 2011-09-13 2011-09-14 0001308027 vyst:CmaNoteMember us-gaap:WarrantMember 2012-11-01 2012-11-02 0001308027 vyst:CmaNoteMember us-gaap:WarrantMember 2013-04-28 2013-04-29 0001308027 vyst:CmaNoteMember us-gaap:WarrantMember 2013-04-29 0001308027 us-gaap:StockCompensationPlanMember 2004-01-01 0001308027 2016-01-01 2016-09-30 0001308027 vyst:CmaNoteMember 2011-04-28 2011-04-29 0001308027 vyst:CmaNoteMember 2017-01-01 2017-09-30 0001308027 us-gaap:ConvertiblePreferredStockMember 2013-05-02 0001308027 us-gaap:ConvertiblePreferredStockMember 2013-05-01 2013-05-02 0001308027 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001308027 us-gaap:StockCompensationPlanMember 2017-09-30 0001308027 us-gaap:WarrantMember us-gaap:MinimumMember 2017-09-30 0001308027 us-gaap:WarrantMember us-gaap:MaximumMember 2017-09-30 0001308027 us-gaap:ConvertibleDebtMember 2017-09-30 0001308027 us-gaap:ConvertibleDebtMember 2017-01-01 2017-09-30 0001308027 us-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-09-30 0001308027 us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-09-30 0001308027 vyst:BusinessDevelopmentAgreementTwoMember 2017-07-29 2017-07-30 0001308027 2015-12-31 0001308027 2016-09-30 0001308027 2016-01-01 2016-12-31 0001308027 us-gaap:ConvertibleDebtMember us-gaap:MaximumMember 2017-09-30 0001308027 vyst:BusinessDevelopmentAgreementOneMember 2017-09-26 2017-09-27 0001308027 us-gaap:ConvertiblePreferredStockMember vyst:Maximum1Member 2013-05-02 0001308027 2017-07-01 2017-09-30 0001308027 2016-07-01 2016-09-30 0001308027 2017-11-14 0001308027 us-gaap:SegmentDiscontinuedOperationsMember 2017-07-01 2017-09-30 0001308027 us-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2016-09-30 0001308027 vyst:CmaNoteMember 2017-09-30 0001308027 us-gaap:PrivatePlacementMember 2017-01-01 2017-09-30 0001308027 us-gaap:StockCompensationPlanMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001308027 us-gaap:StockCompensationPlanMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0001308027 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2017-10-08 2017-10-09 0001308027 us-gaap:ConvertibleDebtMember us-gaap:MinimumMember 2017-09-30 0001308027 us-gaap:ChiefExecutiveOfficerMember 2017-09-22 2017-09-29 0001308027 us-gaap:SubsequentEventMember us-gaap:ChiefExecutiveOfficerMember 2017-11-05 2017-11-06 0001308027 vyst:BlueOarConsultingMember 2017-07-24 2017-07-25 0001308027 vyst:AccentuatePublicRelationsMember 2017-06-29 2017-07-02 0001308027 vyst:AnazcaMember 2017-09-26 2017-09-28 0001308027 us-gaap:SubsequentEventMember vyst:AnazcaMember 2017-10-19 2017-10-20 0001308027 us-gaap:SubsequentEventMember 2017-10-08 2017-10-10 0001308027 us-gaap:WarrantMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001308027 us-gaap:WarrantMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0001308027 us-gaap:StockCompensationPlanMember 2014-01-01 2014-12-31 0001308027 vyst:BusinessDevelopmentAgreementTwoMember 2017-03-14 2017-03-15 0001308027 vyst:BusinessDevelopmentAgreementOneMember 2017-03-14 2017-03-15 0001308027 us-gaap:WarrantMember 2017-04-08 2017-04-09 0001308027 2017-04-24 2017-04-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure vyst:Number Vystar Corp 0001308027 10-Q VYST 2017-09-30 false --12-31 No No Yes Smaller Reporting Company 132189001 Q3 2017

410847

234514

-2613788

-2823210

-27687363

-26814649

25060524

23979943

13050

11495

3024635

3057724

198461

239231

2826174

2818493

339946

231080

591529

595837

2917

394824

488784

1499875 1499875

410847

234514

127802

139562

283045

94952

270954

41300

5440

17370

6651

36282

29059

117640

0.0001

15000000

13828

0.0001

250000000

130495927

114951594

130495927

114951594

11723

37264

5400

29642

11760

3920

278

9718271

8298271

18084609

16469582

2543129

130

80988

4538

42382

43207

47229

-31030

238551

9072

247623

119821

108061

1066136

200000

800000

1000000

1500000

0.0525

1240250

2600000

1600000

2100000

0.27

0.35

0.45

0.10

0.07

0.17

0.20 0.10 100000

16469582

16122332

6300000

693000

630000

789990

0.10

0.05

0.055

19305727

789990

835068

276146

231080

1066136 1066148 198461 239231

200000

500000

250000

1087023

3125000

363985

368217

750000

400000

16 7690000 384500 200000

10.00

2000000

0.10

0.075 0.05 25000 60133

3968269

128461

P4Y

10000000

4000000

618427

P10Y P4Y

50000

8298271

9418271

1120000

6533271

0.16

0.20

P4Y1M6D

P4Y5M5D

1.5082

0.0199

0.10 0.10 0.14 0.05 0.14 0.10

P5Y15D

P6Y1M6D

0.14

200000

0.10

0.05

0.0650

0.0525

-50430

-148688

34803

-54581

128943

134233

43710

40125

78513

-14456

78513

-14456

-864666

-880995

-331182

-220780

860589

902286

331807

247422

860589

902286

331807

247422

-4077

21291

625

26642

15800

15973

4775

3000

-915096

-1029683

-296379

-275361

42382

43207

47229

-31030

-872714

-986476

-249150

-306391

-0.01

0.00

122514759

104995141

127657923

111954708

427998

379301

242038

74253

-414131

-537620

53541

28906

-31159

4666

15487

-52445

-11930

-31766

-60266

2701

384500

623500

53500

384500

570000

-29631

88581

73875

96176

2701

481884

118919

45000

P5Y3M15D

P6Y10M10D

16173221 P6Y4M20D P5Y4M9D 1240250 362216

P11M

.09

P10Y P5Y

5000000

Basis of Presentation   The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (“GAAP”) for interim financial information. Accordingly, certain information and footnotes required by GAAP for complete financial statements may be condensed or omitted. These interim financial statements should be read in conjunction with our audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission (“SEC”). In the opinion of Vystar management, these financial statements contain all adjustments (which comprise only normal and recurring accruals) necessary to present fairly the financial position and results of operations as of and for the three-month and nine-month periods ended September 30, 2017 and 2016.

Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future, actual results could differ from these estimates. Examples include valuation allowances for deferred tax assets, provisions for bad debts, and fair values of share-based compensation.

Concentration of Credit Risk   Certain financial instruments potentially subject the Company to concentrations of credit risk. These financial instruments consist primarily of cash and accounts receivable. Cash held in banks in many cases exceeds the Federal Deposit Insurance Corporation, or FDIC, insurance limits. While we monitor our cash balances on a regular basis and adjust the balances as appropriate, these balances could be impacted if the underlying financial institutions fail. To date, we have experienced no loss or lack of access to our cash; however, we can provide no assurances that access to our cash will not be impacted by adverse conditions in the financial markets.

Loss Per Share   Because the Company reported a net loss for the nine-month periods ended September 30, 2017 and 2016, common stock equivalents, including stock options and warrants, were anti-dilutive; therefore, the amounts reported for basic and diluted loss per share were the same. Excluded from the computation of diluted loss per share were options outstanding to purchase 8,298,271 shares and 9,718,271 shares of common stock for the nine months ended September 30, 2017 and 2016, respectively, as their effect would be anti-dilutive. Warrants to purchase 16,469,582 and 18,084,609 shares of common stock for the nine months ended September 30, 2017 and 2016, respectively, were also excluded from the computation of diluted loss per share as their effect would be anti-dilutive.

Fair Value of Financial Instruments   The Company’s financial instruments consist of cash, accounts receivable, accounts payable, accrued expenses, line of credit and shareholder notes payable. The carrying values of all the Company’s financial instruments approximate fair value because of their short maturities. In addition to the short maturities, the carrying amounts of our line of credit and shareholder notes payable approximate fair value because the interest rates at September 30, 2017 approximate market interest rates for the respective borrowings.   In specific circumstances, certain assets and liabilities are reported or disclosed at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the Company’s principal market for such transactions. If there is not an established principal market, fair value is derived from the most advantageous market.   Valuation inputs are classified in the following hierarchy:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 3%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 4%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif">●</td> <td style="width: 93%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif">Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif">●</td> <td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif">Level 2 inputs are directly or indirectly observable valuation inputs for the asset or liability, excluding Level 1 inputs.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif">●</td> <td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif">Level 3 inputs are unobservable inputs for the asset or liability.</td></tr> </table>   Highest priority is given to Level 1 inputs and the lowest priority to Level 3 inputs. Acceptable valuation techniques include the market approach, income approach, and cost approach. In some cases, more than one valuation technique is used.

Intangible assets are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2017</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="width: 70%; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Patents</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">238,551</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">238,551</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Trademarks & trade name</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,072</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,072</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Subtotal</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">247,623</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">247,623</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(119,821</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(108,061</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt; padding-left: 5.4pt"> Intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">127,802</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">139,562</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

The following table summarizes the shareholder notes payable:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2017</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Shareholder notes</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">789,990</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">835,068</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accrued Interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">276,146</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">231,080</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Total Shareholder Notes & Accrued Interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,066,136</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,066,148</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Less: Accrued Interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(276,146</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(231,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 5.4pt">Less: Current Portion</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(591,529</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(595,837</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 20pt; padding-left: 5.4pt"> Total long-term debt</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">198,461</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">239,231</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif"><td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif">NOTE 9</td><td style="font: 10pt Times New Roman, Times, Serif">SHARE-BASED COMPENSATION</td> </tr></table>   Generally accepted accounting principles require share-based payments to employees, including grants of employee stock options, warrants, and common stock to be recognized in the income statement based on their fair values at the date of grant, net of estimated forfeitures.   In total, the Company recorded $424,038 and $74,253 of stock-based compensation expense for the three-month period ended September 30, 2017 and 2016, respectively, and $642,165 and $379,301 of stock-based compensation expense for the nine-month period ended September 30, 2017, and 2016, respectively related to employee and board member stock options and common stock and warrants issued to nonemployees. As of September 30, 2017, $128,461 of unrecognized compensation expense related to non-vested share-based awards remains to be recognized over a period of approximately four years.   Options and Warrants   The Company used the Black-Scholes option pricing model to estimate the grant-date fair value of option and warrant awards granted. The following assumptions were used for warrant awards during the nine months ended September 30, 2017:   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">●</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Expected Dividend Yield – because we do not currently pay dividends, the expected dividend yield is zero;</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">●</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Expected Volatility in Stock Price – volatility based on our own trading activity was used to determine expected volatility;</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">●</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Risk-free Interest Rate – reflects the average rate on a United States Treasury Bond with a maturity equal to the expected term of the option; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">●</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Expected Life of Award – because we have minimal experience with the exercise of options or warrants for use in determining the expected life of each award, we used the option or warrant’s contractual term as the expected life.</td></tr></table>   Options   During 2004, the Board of Directors of the Company adopted a stock option plan (the “Plan”) and authorized up to 4,000,000 shares to be issued under the Plan. In April 2009, the Company’s Board of Directors authorized an increase in the number of shares to be issued under the Plan to 10,000,000 shares and to include the independent Board Members in the Plan in lieu of continuing the previous practice of granting warrants each quarter to independent Board Members for services. At September 30, 2017, there were 618,427 shares of common stock reserved for issuance under the Plan. In 2014, the Board adopted an additional stock option plan which provides for an additional 5,000,000 shares which are all available as of December 31, 2016. The Plan is intended to permit stock options granted to employees to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”). All options granted under the Plan that are not intended to qualify as Incentive Stock Options are deemed to be non-qualified options. Stock options are granted at an exercise price equal to the fair market value of the Company’s common stock on the date of grant, typically vest over periods up to 4 years and are typically exercisable up to 10 years.   There were no options granted during the nine-month period ended September 30, 2017. The following table summarizes all stock option activity of the Company for the period.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="width: 54%; font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2016</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">9,418,271</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.16</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.43</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expired</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,120,000</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, September 30, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,298,271</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.16</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.10</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercisable, September 30, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,533,271</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.20</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.29</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>   Warrants   Warrants are issued to employees for expenses and for compensation in lieu of cash as well as to third parties as payment for services and in conjunction with the issuance of common stock. The fair value of each common stock warrant issued for services is estimated on the date of grant using the Black-Scholes option pricing model.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td colspan="5" style="font: 10pt Times New Roman, Times, Serif">The weighted-average assumptions used in the option pricing model for stock warrant grants were as follows:</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Expected Dividend Yield</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Expected Volatility in Stock Price</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">150.82</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Risk-Free Interest Rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.99</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Expected Life of Stock Awards – Years</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.86</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>   The following table represents the Company’s warrant activity for the nine months ended September 30, 2017:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Contractual  Life (Years)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="width: 39%; font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2016</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">16,122,332</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.10</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">6.10</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,240,250</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.39</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(200,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(693,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expired</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, September 30, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,469,582</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.10</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.04</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercisable, September 30, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,173,221</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.10</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.36</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>   The Company issued 1,240,250 warrants for services during the nine months ended September 30, 2017 at exercise prices from $0.07 to $0.17 per share, exercisable over a period of five to ten years from the grant date. All of the warrants with the exception of 362,219 vested immediately with the 362,219 warrants vesting one-eleventh per month over an eleven-month period. The total amount of the fair value of this grant was $50,000 and is recorded as noncash share-based compensation expense as vesting occurs. The fair value of the warrants was calculated as of the date of the grant utilizing the Black-Scholes option pricing model and assumptions as detailed above.

The following table summarizes all stock option activity of the Company for the period.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="width: 54%; font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2016</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">9,418,271</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.16</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.43</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expired</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,120,000</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, September 30, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,298,271</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.16</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.10</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercisable, September 30, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,533,271</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.20</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.29</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

The following table represents the Company’s warrant activity for the nine months ended September 30, 2017:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Contractual  Life (Years)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="width: 39%; font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, December 31, 2016</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">16,122,332</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.10</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">6.10</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,240,250</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.39</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(200,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(693,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expired</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding, September 30, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,469,582</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.10</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.04</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercisable, September 30, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,173,221</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.10</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.36</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="font: 10pt Times New Roman, Times, Serif"><td colspan="5" style="font: 10pt Times New Roman, Times, Serif">The weighted-average assumptions used in the option pricing model for stock warrant grants were as follows:</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Expected Dividend Yield</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Expected Volatility in Stock Price</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">150.82</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Risk-Free Interest Rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.99</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Expected Life of Stock Awards – Years</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.86</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

214167

Revenues   The Company derives revenue from license fees of Vytex NRL raw material to manufacturers and distributors of rubber and rubber-end products such as the foam used in the pillows and mattresses. Revenue is recognized when the licensee confirms payment and pays Vystar.

642165

379301

242038

74253

55470

1109406

EX-101.SCH 6 vyst-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF OPERATIONS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LIQUIDITY AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTES PAYABLE AND LOAN FACILITY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - NOTES PAYABLE AND LOAN FACILITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - NOTES PAYABLE AND LOAN FACILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - NOTES PAYABLE AND LOAN FACILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vyst-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vyst-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vyst-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Antidilutive Securities [Axis] Stock Options [Member] Warrant [Member] Award Type [Axis] Stock Option Plan [Member] Debt Instrument [Axis] CMA Note [Member] Class of Warrant or Right [Axis] Warrant [Member] Class of Stock [Axis] 10% Series A Cumulative Convertible Preferred Stock [Member] Range [Axis] Minimum [Member] Maximum [Member] Long-term Debt, Type [Axis] Shareholders Convertible Promissory Notes [Member] Disposal Group Classification [Axis] Kiron Division [Member] Other Commitments [Axis] Business Development Agreement - Joseph Zampeti [Member] Business Development Agreement - FMW Media Works [Member] Additional Investment [Member] Sale of Stock [Axis] November 2016 Private Placement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Related Party [Axis] Chief Executive Officer [Member] Blue Oar Consulting [Member] Accentuate Public Relations [Member] Anazca, LLC [Member] Business Development Agreement - Joseph Savanyo [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Trading Symbol Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Accounts receivable, net of allowance for uncollectible amount of $0 at September 30, 2017 and December 31, 2016, respectively Prepaid expenses TOTAL CURRENT ASSETS OTHER ASSETS Intangible assets, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Related party line of credit Accounts payable Accrued compensation Shareholder notes payable Accrued expenses TOTAL CURRENT LIABILITIES Shareholder notes payable TOTAL LIABILITIES STOCKHOLDERS' DEFICIT Preferred stock, $0.0001 par value, 15,000,000 shares authorized; 13,828 issued and outstanding at September 30, 2017 and December 31, 2016 respectively Common stock, $0.0001 par value, 250,000,000 shares authorized; 130,495,927 and 114,951,594 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS' DEFICIT TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Allowances, account receivable Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] REVENUE COST OF REVENUE Gross Margin OPERATING EXPENSES General and administrative, including non-cash share-based compensation of $242,038 and $74,253 for the three months ended September 30, 2017 and 2016, respectively and $427,998 and $379,301 for the nine months ended September 30, 2017 and 2016, respectively Total Operating Expenses LOSS FROM OPERATIONS OTHER INCOME (EXPENSE) Interest income Other income Interest expense Total Other Income (Expense) LOSS FROM CONTINUING OPERATIONS INCOME (LOSS) FROM DISCONTINUED OPERATIONS NET LOSS BASIC AND DILUTED LOSS PER SHARE: Net loss per share (in dollars per share) Basic and Diluted Weighted Average Number of Common Shares Outstanding (in shares) Share-based compensation Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to cash used in operating activities Allowance for uncollectible accounts receivable Depreciation Amortization of intangible assets (Increase) decrease in assets Accounts receivable Prepaid expenses Increase (decrease) in liabilities Accounts payable Accrued compensation and expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Disposal of equipment, net Net cash provided by investing activities CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common stock, net of costs Exercise of warrants/options Net cash provided by financing activities NET INCREASE (DECREASE) IN CASH CASH - BEGINNING OF YEAR CASH - END OF PERIOD SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: NON-CASH TRANSACTIONS Common stock issued for services to be rendered Shareholder notes converted to common stock CASH PAID DURING THE PERIOD FOR Interest Description Of Business DESCRIPTION OF BUSINESS Accounting Policies [Abstract] BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Liquidity And Going Concern LIQUIDITY AND GOING CONCERN Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS Income Tax Disclosure [Abstract] INCOME TAXES Debt Disclosure [Abstract] NOTES PAYABLE AND LOAN FACILITY Stockholders' Equity Note [Abstract] STOCKHOLDERS' EQUITY Disclosure of Compensation Related Costs, Share-based Payments [Abstract] SHARE-BASED COMPENSATION Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Estimates Concentration of Credit Risk Loss Per Share Revenues Fair Value of Financial Instruments Schedule of intangible assets Schedule of Shareholder Notes Payable Schedule of stock option activity Schedule of weighted-average assumptions used in the option pricing model for stock warrant grants Schedule of warrant activity Statement [Table] Statement [Line Items] Antidilutive securities excluded from computation of earnings per share, amount Liquidity And Going Concern Details Narrative Working capital deficit Revenue from discontinued operations Gains (losses) from discontinued operations Patents Trademarks & trade name Subtotal Accumulated amortization Intangible assets, net Shareholder notes Accrued Interest Total Shareholder Notes & Accrued Interest Less : Accrued Interest Less : Current Portion Total long-term debt Shareholder notes payable plus accrued interest Increase in line of credit Line of Credit Facility, Maximum Borrowing Capacity Basis Spread on Variable Rate, During Period Debt, Interest Rate Debt, Weighted Average Interest Rate Grant of warrants Warrant exercise price (per share) Percentage of Common Stock Shares Vested Immediately on Directors by Conversion of Warrants Percentage of Common Stock Shares Vesting on Directors Upon Each Draw by Conversion of Warrants Minimum Amount of Line of Credit Drawn For Vesting of Portion of Common Stock Granted to Directors As Compensation Total number of warrants outstanding EX-101.PRE 10 vyst-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 14, 2017
Document And Entity Information
Entity Registrant Name	Vystar Corp
Entity Central Index Key	0001308027
Document Type	10-Q
Trading Symbol	VYST
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		132,189,001
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

XML 12 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash	$ 6,651	$ 36,282
Accounts receivable, net of allowance for uncollectible amount of $0 at September 30, 2017 and December 31, 2016, respectively	5,440	17,370
Prepaid expenses	270,954	41,300
TOTAL CURRENT ASSETS	283,045	94,952
OTHER ASSETS
Intangible assets, net	127,802	139,562
TOTAL ASSETS	410,847	234,514
CURRENT LIABILITIES
Related party line of credit	1,499,875	1,499,875
Accounts payable	394,824	488,784
Accrued compensation		2,917
Shareholder notes payable	591,529	595,837
Accrued expenses	339,946	231,080
TOTAL CURRENT LIABILITIES	2,826,174	2,818,493
Shareholder notes payable	198,461	239,231
TOTAL LIABILITIES	3,024,635	3,057,724
STOCKHOLDERS' DEFICIT
Preferred stock, $0.0001 par value, 15,000,000 shares authorized; 13,828 issued and outstanding at September 30, 2017 and December 31, 2016 respectively	1	1
Common stock, $0.0001 par value, 250,000,000 shares authorized; 130,495,927 and 114,951,594 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	13,050	11,495
Additional paid-in capital	25,060,524	23,979,943
Accumulated deficit	(27,687,363)	(26,814,649)
TOTAL STOCKHOLDERS' DEFICIT	(2,613,788)	(2,823,210)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 410,847	$ 234,514

XML 13 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowances, account receivable	$ 0	$ 0
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	15,000,000	15,000,000
Preferred stock, issued	13,828	13,828
Preferred stock, outstanding	13,828	13,828
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	250,000,000	250,000,000
Common stock, issued	130,495,927	114,951,594
Common stock, outstanding	130,495,927	114,951,594

XML 14 R4.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
STATEMENTS OF OPERATIONS (unaudited) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
REVENUE	$ 5,400	$ 29,642	$ 11,723	$ 37,264
COST OF REVENUE	4,775	3,000	15,800	15,973
Gross Margin	625	26,642	(4,077)	21,291
OPERATING EXPENSES
General and administrative, including non-cash share-based compensation of $242,038 and $74,253 for the three months ended September 30, 2017 and 2016, respectively and $427,998 and $379,301 for the nine months ended September 30, 2017 and 2016, respectively	331,807	247,422	860,589	902,286
Total Operating Expenses	331,807	247,422	860,589	902,286
LOSS FROM OPERATIONS	(331,182)	(220,780)	(864,666)	(880,995)
OTHER INCOME (EXPENSE)
Interest income				1
Other income	78,513	(14,456)	78,513	(14,456)
Interest expense	(43,710)	(40,125)	(128,943)	(134,233)
Total Other Income (Expense)	34,803	(54,581)	(50,430)	(148,688)
LOSS FROM CONTINUING OPERATIONS	(296,379)	(275,361)	(915,096)	(1,029,683)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS	47,229	(31,030)	42,382	43,207
NET LOSS	$ (249,150)	$ (306,391)	$ (872,714)	$ (986,476)
BASIC AND DILUTED LOSS PER SHARE:
Net loss per share (in dollars per share)	$ 0.00	$ 0.00	$ (0.01)	$ (0.01)
Basic and Diluted Weighted Average Number of Common Shares Outstanding (in shares)	127,657,923	111,954,708	122,514,759	104,995,141

XML 15 R5.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATIONS (unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Share-based compensation	$ 242,038	$ 74,253	$ 427,998	$ 379,301

XML 16 R6.htm IDEA: XBRL DOCUMENT

STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	9 Months Ended
STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (872,714)	$ (986,476)
Adjustments to reconcile net loss to cash used in operating activities
Share-based compensation	427,998	379,301
Allowance for uncollectible accounts receivable		(60,266)
Depreciation		278
Amortization of intangible assets	11,760	11,760
(Increase) decrease in assets
Accounts receivable	11,930	31,766
Prepaid expenses	(15,487)	52,445
Increase (decrease) in liabilities
Accounts payable	(31,159)	4,666
Accrued compensation and expenses	53,541	28,906
Net cash used in operating activities	(414,131)	(537,620)
CASH FLOWS FROM INVESTING ACTIVITIES
Disposal of equipment, net		2,701
Net cash provided by investing activities		2,701
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock, net of costs	384,500	570,000
Exercise of warrants/options		53,500
Net cash provided by financing activities	384,500	623,500
NET INCREASE (DECREASE) IN CASH	(29,631)	88,581
CASH - BEGINNING OF YEAR	36,282	29,059
CASH - END OF PERIOD	6,651	117,640
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: NON-CASH TRANSACTIONS
Common stock issued for services to be rendered	214,167
Shareholder notes converted to common stock	55,470
CASH PAID DURING THE PERIOD FOR
Interest	$ 73,875	$ 96,176

XML 17 R7.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS

9 Months Ended

Sep. 30, 2017

Description Of Business

DESCRIPTION OF BUSINESS

NOTE 1

DESCRIPTION OF BUSINESS

XML 18 R8.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Estimates

Concentration of Credit Risk

Loss Per Share

Revenues

Fair Value of Financial Instruments

Valuation inputs are classified in the following hierarchy:

	●	Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
	●	Level 2 inputs are directly or indirectly observable valuation inputs for the asset or liability, excluding Level 1 inputs.
	●	Level 3 inputs are unobservable inputs for the asset or liability.

XML 19 R9.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND GOING CONCERN

9 Months Ended

Sep. 30, 2017

Liquidity And Going Concern

LIQUIDITY AND GOING CONCERN

NOTE 3

LIQUIDITY AND GOING CONCERN

XML 20 R10.htm IDEA: XBRL DOCUMENT

DISCONTINUED OPERATIONS

9 Months Ended

Sep. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS

NOTE 4

DISCONTINUED OPERATIONS

XML 21 R11.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 5

INTANGIBLE ASSETS

Intangible assets are as follows:

	September 30, 2017			December 31, 2016

Patents	$	238,551		$	238,551
Trademarks & trade name		9,072			9,072
Subtotal		247,623			247,623
Accumulated amortization		(119,821	)		(108,061	)

Intangible assets, net	$	127,802		$	139,562

Amortization expense for the three months ended September 30, 2017 and 2016 was $3,920. Amortization expense for the nine months ended September 30, 2017 and 2016 was $11,760.

XML 22 R12.htm IDEA: XBRL DOCUMENT

INCOME TAXES

9 Months Ended

Sep. 30, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 6

INCOME TAXES

XML 23 R13.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LOAN FACILITY

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

NOTES PAYABLE AND LOAN FACILITY

NOTE 7

NOTES PAYABLE AND LOAN FACILITY

Related Party Line of Credit (CMA Note Payable)

Other terms of the CMA Note include:

●

The Note is unsecured;

●

No payments of principal are due until the second anniversary of the Note, at which time all outstanding principal is due and payable; and

●

On April 30, 2014, the maturity date of the CMA Note was extended to April 30, 2015. No consideration was awarded the CMA members based on this extension.

On April 29, 2015, the maturity date of the CMA Note was extended to April 29, 2016. No consideration was awarded the CMA members based on this extension. The note is currently due on demand.

Shareholder Notes Payable

The following table summarizes the shareholder notes payable:

	September 30, 2017			December 31, 2016

Shareholder notes	$	789,990		$	835,068
Accrued Interest		276,146			231,080
Total Shareholder Notes & Accrued Interest		1,066,136			1,066,148

Less: Accrued Interest		(276,146	)		(231,080	)
Less: Current Portion		(591,529	)		(595,837	)
Total long-term debt	$	198,461		$	239,231

XML 24 R14.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

STOCKHOLDERS' EQUITY

NOTE 8

STOCKHOLDERS’ EQUITY

Common Stock and Warrants

On April 9, 2017, the Company issued 118,919 common shares as a result of a cashless exercise of outstanding warrants.

On April 25, 2017, the Company issued 1,109,406 common shares as a result of a partial conversion of a Shareholder Note and accrued interest.

On September 29, 2017, the Company issued 500,000 shares of common stock as part of the existing PPM to William Doyle, its CEO in lieu of salary earned in August and September 2017.

On September 27, 2017, the Company issued an additional 200,000 common shares as compensation under the Company’s Business Development Agreement with FMW Media Works Corporation and on July 30, 2017 200,000 common shares as compensation under the Company’s Business Development Agreement with Joseph Zampetti. On July 25, 2017, the Company issued 1,087,023 shares (dated June 29, 2017) to Blue Oar Consulting, Inc. as part of a prior contract.

On July 1, 2017 the Company issued 3,125,000 shares to Accentuate Public Relations LLC under the Company’s Public Relations Services Agreement through December 2018.

Cumulative Convertible Preferred Stock

XML 25 R15.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

SHARE-BASED COMPENSATION

NOTE 9

SHARE-BASED COMPENSATION

In total, the Company recorded $424,038 and $74,253 of stock-based compensation expense for the three-month period ended September 30, 2017 and 2016, respectively, and $642,165 and $379,301 of stock-based compensation expense for the nine-month period ended September 30, 2017, and 2016, respectively related to employee and board member stock options and common stock and warrants issued to nonemployees. As of September 30, 2017, $128,461 of unrecognized compensation expense related to non-vested share-based awards remains to be recognized over a period of approximately four years.

Options and Warrants

●

Expected Dividend Yield – because we do not currently pay dividends, the expected dividend yield is zero;

●

Expected Volatility in Stock Price – volatility based on our own trading activity was used to determine expected volatility;

●

Risk-free Interest Rate – reflects the average rate on a United States Treasury Bond with a maturity equal to the expected term of the option; and

●

Options

There were no options granted during the nine-month period ended September 30, 2017. The following table summarizes all stock option activity of the Company for the period.

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)

Outstanding, December 31, 2016		9,418,271	$	0.16		4.43

Granted		—

Exercised		—

Expired		1,120,000

Outstanding, September 30, 2017		8,298,271	$	0.16		4.10

Exercisable, September 30, 2017		6,533,271	$	0.20		5.29

Warrants

The weighted-average assumptions used in the option pricing model for stock warrant grants were as follows:

	2017
Expected Dividend Yield	0.00	%
Expected Volatility in Stock Price	150.82	%
Risk-Free Interest Rate	1.99	%
Expected Life of Stock Awards – Years	6.86

The following table represents the Company’s warrant activity for the nine months ended September 30, 2017:

	Number of Shares			Weighted Average Grant Date Fair Value		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)

Outstanding, December 31, 2016		16,122,332				$	0.10		6.10

Granted		1,240,250		$	0.14	$	0.14		6.39

Exercised		(200,000	)			$	0.05

Forfeited		(693,000	)			$	0.14

Expired		—

Outstanding, September 30, 2017		16,469,582				$	0.10		5.04

Exercisable, September 30, 2017		16,173,221				$	0.10		5.36

XML 26 R16.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 10

SUBSEQUENT EVENTS

On October 9, 2017, the Company issued 481,884 common shares as a result of a cashless exercise of outstanding warrants.

On October 10, 2017, the Company issued Shareholder Notes for a total of $45,000.

On October 20, 2017, the Company issued Anazca 368,217 shares as a quarterly commitment. Anazca, LLC subsequently resigned from their contract effective November 3, 2017.

On November 6, 2017, the Company issued 250,000 shares of common stock as part of the existing PPM to William Doyle, its CEO in lieu of salary earned during October 2017.

XML 27 R17.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Estimates

Estimates

Concentration of Credit Risk

Concentration of Credit Risk

Loss Per Share

Loss Per Share

Revenues

Revenues

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Valuation inputs are classified in the following hierarchy:

	●	Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
	●	Level 2 inputs are directly or indirectly observable valuation inputs for the asset or liability, excluding Level 1 inputs.
	●	Level 3 inputs are unobservable inputs for the asset or liability.

XML 28 R18.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

Intangible assets are as follows:

	September 30, 2017			December 31, 2016

Patents	$	238,551		$	238,551
Trademarks & trade name		9,072			9,072
Subtotal		247,623			247,623
Accumulated amortization		(119,821	)		(108,061	)

Intangible assets, net	$	127,802		$	139,562

XML 29 R19.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LOAN FACILITY (Tables)

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Schedule of Shareholder Notes Payable

The following table summarizes the shareholder notes payable:

	September 30, 2017			December 31, 2016

Shareholder notes	$	789,990		$	835,068
Accrued Interest		276,146			231,080
Total Shareholder Notes & Accrued Interest		1,066,136			1,066,148

Less: Accrued Interest		(276,146	)		(231,080	)
Less: Current Portion		(591,529	)		(595,837	)
Total long-term debt	$	198,461		$	239,231

XML 30 R20.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of stock option activity

The following table summarizes all stock option activity of the Company for the period.

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)

Outstanding, December 31, 2016		9,418,271	$	0.16		4.43

Granted		—

Exercised		—

Expired		1,120,000

Outstanding, September 30, 2017		8,298,271	$	0.16		4.10

Exercisable, September 30, 2017		6,533,271	$	0.20		5.29

Schedule of weighted-average assumptions used in the option pricing model for stock warrant grants

The weighted-average assumptions used in the option pricing model for stock warrant grants were as follows:

	2017
Expected Dividend Yield	0.00	%
Expected Volatility in Stock Price	150.82	%
Risk-Free Interest Rate	1.99	%
Expected Life of Stock Awards – Years	6.86

Schedule of warrant activity

The following table represents the Company’s warrant activity for the nine months ended September 30, 2017:

	Number of Shares			Weighted Average Grant Date Fair Value		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)

Outstanding, December 31, 2016		16,122,332				$	0.10		6.10

Granted		1,240,250		$	0.14	$	0.14		6.39

Exercised		(200,000	)			$	0.05

Forfeited		(693,000	)			$	0.14

Expired		—

Outstanding, September 30, 2017		16,469,582				$	0.10		5.04

Exercisable, September 30, 2017		16,173,221				$	0.10		5.36

XML 31 R21.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Stock Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount	8,298,271	9,718,271
Warrant [Member]
Antidilutive securities excluded from computation of earnings per share, amount	16,469,582	18,084,609

XML 32 R22.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Liquidity And Going Concern Details Narrative
Cash	$ 6,651	$ 36,282	$ 117,640	$ 29,059
Working capital deficit	2,543,129
Accumulated deficit	$ (27,687,363)	$ (26,814,649)

XML 33 R23.htm IDEA: XBRL DOCUMENT

DISCONTINUED OPERATIONS (Details Narrative) - Kiron Division [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue from discontinued operations	$ 0	$ 4,538	$ 130	$ 80,988
Gains (losses) from discontinued operations	$ 47,229	$ (31,030)	$ 42,382	$ 43,207

XML 34 R24.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 238,551	$ 238,551
Trademarks & trade name	9,072	9,072
Subtotal	247,623	247,623
Accumulated amortization	(119,821)	(108,061)
Intangible assets, net	$ 127,802	$ 139,562

XML 35 R25.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
INTANGIBLE ASSETS (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 3,920	$ 3,920	$ 11,760	$ 11,760

XML 36 R26.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LOAN FACILITY (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Shareholder notes	$ 789,990	$ 835,068
Accrued Interest	276,146	231,080
Total Shareholder Notes & Accrued Interest	1,066,136	1,066,148
Less : Accrued Interest	(276,146)	(231,080)
Less : Current Portion	(591,529)	(595,837)
Total long-term debt	$ 198,461	$ 239,231

XML 37 R27.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LOAN FACILITY (Details Narrative) - USD ($)					9 Months Ended
	Apr. 29, 2013	Nov. 02, 2012	Sep. 14, 2011	Apr. 29, 2011	Sep. 30, 2017	Dec. 31, 2016
Grant of warrants					1,240,250
Total number of warrants outstanding					16,469,582	16,122,332
Number of warrants forfeited					693,000
Shareholders Convertible Promissory Notes [Member]
Shareholder notes payable plus accrued interest					$ 1,066,136
Debt instrument face amount					$ 789,990
Average conversion price of debt (per share)					$ 0.055
Conversion of debt equivalent shares					19,305,727
Shareholders Convertible Promissory Notes [Member] \| Minimum [Member]
Debt instrument interest rate					5.00%
Conversion price of debt (per share)					$ 0.05
Shareholders Convertible Promissory Notes [Member] \| Maximum [Member]
Debt instrument interest rate					10.00%
Conversion price of debt (per share)					$ 0.10
Warrant [Member] \| Minimum [Member]
Warrant exercise price (per share)					0.07
Warrant [Member] \| Maximum [Member]
Warrant exercise price (per share)					$ 0.17
CMA Note [Member]
Increase in line of credit			$ 200,000
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,500,000	$ 1,000,000	$ 800,000
Basis Spread on Variable Rate, During Period				5.25%
Debt, Interest Rate					6.50%
Debt, Weighted Average Interest Rate					5.25%
Warrant exercise price (per share)		$ 0.35	$ 0.27
CMA Note [Member] \| Warrant [Member]
Grant of warrants		2,100,000	1,600,000	2,600,000
Warrant exercise price (per share)	$ 0.10			$ 0.45
Percentage of Common Stock Shares Vested Immediately on Directors by Conversion of Warrants				20.00%
Percentage of Common Stock Shares Vesting on Directors Upon Each Draw by Conversion of Warrants				10.00%
Minimum Amount of Line of Credit Drawn For Vesting of Portion of Common Stock Granted to Directors As Compensation				$ 100,000
Total number of warrants outstanding	6,300,000
Number of warrants forfeited	630,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative)											9 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative)	Sep. 29, 2017 shares	Sep. 28, 2017 shares	Sep. 27, 2017 shares	Jul. 30, 2017 shares	Jul. 25, 2017 shares	Jul. 02, 2017 shares	Apr. 25, 2017 shares	Apr. 09, 2017 shares	Mar. 15, 2017 shares	May 02, 2013 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) Number shares	Dec. 31, 2016 shares
Preferred stock,, shares outstanding											13,828	13,828
Accumulated undeclared dividends of preferred stock \| $											$ 60,133
Number of shares issuable upon conversion of preferred stock											3,968,269
Number of shares issued for the partial conversion of a Shareholder Note and accrued interest							1,109,406
Warrant [Member]
Number of shares issued for a a cashless exercise of outstanding warrants								118,919
Chief Executive Officer [Member]
Common stock issued for services, shares	500,000
Business Development Agreement - Joseph Zampeti [Member]
Common stock issued for services, shares				200,000					750,000
Business Development Agreement - FMW Media Works [Member]
Common stock issued for services, shares			200,000						400,000
Blue Oar Consulting [Member]
Common stock issued for services, shares					1,087,023
Accentuate Public Relations [Member]
Common stock issued for services, shares						3,125,000
Anazca, LLC [Member]
Common stock issued for services, shares		363,985
November 2016 Private Placement [Member]
Number of accredited investors of private placcement \| Number											16
Common stock issued in private placement \| $											$ 7,690,000
Common stock issued in private placement, shares											384,500
10% Series A Cumulative Convertible Preferred Stock [Member]
Preferred stock, shares in private placement offering										200,000
Price per share \| $ / shares										$ 10.00
Preferred stock value in private placement offering \| $										$ 2,000,000
Preferred stock, dividend rate										10.00%
Preferred stock, stated conversion rate \| $ / shares										$ 0.075
10% Series A Cumulative Convertible Preferred Stock [Member] \| Additional Investment [Member]
Preferred stock, stated conversion rate \| $ / shares										$ 0.05
Additional investment lowering conversion price \| $										$ 25,000

XML 39 R29.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION (Details) - $ / shares	9 Months Ended	12 Months Ended
SHARE-BASED COMPENSATION (Details) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Number of options:
Number of Options outstanding, beginning	9,418,271
Number of Options expired	1,120,000
Number of Options outstanding, ending	8,298,271	9,418,271
Number of Options exercisable	6,533,271
Weighted Average Exercise Price:
Options outstanding,, beginning	$ 0.16
Options outstanding, ending	0.16	$ 0.16
Options exercisable	$ 0.20
Weighted Average Remaining Contractual Life (Years)
Options outstanding	4 years 1 month 6 days	4 years 5 months 5 days
Options exercisable	5 years 3 months 15 days

XML 40 R30.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION (Details 1) - Warrant [Member]	9 Months Ended
SHARE-BASED COMPENSATION (Details 1) - Warrant [Member]	Sep. 30, 2017
Expected Dividend Rate	0.00%
Expected Volatility in Stock price	150.82%
Risk Free Interest Rate	1.99%
Expected Term	6 years 10 months 10 days

XML 41 R31.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION (Details 2) - $ / shares	9 Months Ended	12 Months Ended
SHARE-BASED COMPENSATION (Details 2) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Number of Warrant:
Number of Warrant outstanding, beginning	16,122,332
Number of Warrant granted	1,240,250
Number of Warrant exercised	(200,000)
Number of Warrant forfeited	(693,000)
Number of Warrant outstanding, ending	16,469,582	16,122,332
Number of Warrant exercisable	16,173,221
Warrant Weighted Average Exercise Price:
Warrant outstanding, beginning	$ 0.10
Warrant granted	0.14
Warrant exercised	0.05
Warrant forfeited	0.14
Warrant outstanding, ending	0.10	$ 0.10
Warrant exercisable	$ 0.10
Weighted Average Remaining Contractual Life
Warrant granted	6 years 4 months 20 days
Warrant outstanding	5 years 15 days	6 years 1 month 6 days
Warrant exercisable	5 years 4 months 9 days
Weighted average grant date fair value	$ 0.14

XML 42 R32.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
SHARE-BASED COMPENSATION (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2014	Apr. 30, 2009	Jan. 01, 2004
Share-based compensation	$ 242,038	$ 74,253	$ 642,165	$ 379,301
Unrecognized compensation cost for non-vested awards	$ 128,461		$ 128,461
Period for recognizition of non-vested awards compensation cost			4 years
Warrant [Member]
Vesting period award			11 months
Vesting percent			9.00%
Fair value grant date of warrants			$ 50,000
Warrants issued for services, shares			1,240,250
Number of warrants granted not vested			362,216
Warrant [Member] \| Minimum [Member]
Exercisable period of warrants			5 years
Warrant exercise price	$ 0.07		$ 0.07
Warrant [Member] \| Maximum [Member]
Exercisable period of warrants			10 years
Warrant exercise price	$ 0.17		$ 0.17
Stock Option Plan [Member]
Number of shares authorized under stock option plan						10,000,000	4,000,000
Additional shares authorized					5,000,000
Number of shares reserved for issuance	618,427		618,427
Stock Option Plan [Member] \| Minimum [Member]
Exercisable period of stock options			4 years
Stock Option Plan [Member] \| Maximum [Member]
Exercisable period of stock options			10 years

XML 43 R33.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Nov. 06, 2017	Oct. 20, 2017	Oct. 10, 2017	Oct. 09, 2017	Sep. 29, 2017	Sep. 28, 2017	Apr. 09, 2017
Anazca, LLC [Member]
Common stock issued for services, shares						363,985
Chief Executive Officer [Member]
Common stock issued for services, shares					500,000
Warrant [Member]
Common stock issued upon cashless exercise of warrants, shares							118,919
Subsequent Event [Member]
Proceeds from shareholder notes			$ 45,000
Subsequent Event [Member] \| Anazca, LLC [Member]
Common stock issued for services, shares		368,217
Subsequent Event [Member] \| Chief Executive Officer [Member]
Common stock issued for services, shares	250,000
Subsequent Event [Member] \| Warrant [Member]
Common stock issued upon cashless exercise of warrants, shares				481,884

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 64 177 1 false 19 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://vytex.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS Sheet http://vytex.com/role/BalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://vytex.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS (unaudited) Sheet http://vytex.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS (unaudited) Statements 4 false false R5.htm 00000005 - Statement - STATEMENTS OF OPERATIONS (unaudited) (Parenthetical) Sheet http://vytex.com/role/StatementsOfOperationsParenthetical STATEMENTS OF OPERATIONS (unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - STATEMENTS OF CASH FLOWS (unaudited) Sheet http://vytex.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS (unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://vytex.com/role/DescriptionOfBusiness DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 00000008 - Disclosure - BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://vytex.com/role/BasisOfPresentationSummaryOfSignificantAccountingPolicies BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - LIQUIDITY AND GOING CONCERN Sheet http://vytex.com/role/LiquidityAndGoingConcern LIQUIDITY AND GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - DISCONTINUED OPERATIONS Sheet http://vytex.com/role/DiscontinuedOperations DISCONTINUED OPERATIONS Notes 10 false false R11.htm 00000011 - Disclosure - INTANGIBLE ASSETS Sheet http://vytex.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 11 false false R12.htm 00000012 - Disclosure - INCOME TAXES Sheet http://vytex.com/role/IncomeTaxes INCOME TAXES Notes 12 false false R13.htm 00000013 - Disclosure - NOTES PAYABLE AND LOAN FACILITY Notes http://vytex.com/role/NotesPayableAndLoanFacility NOTES PAYABLE AND LOAN FACILITY Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://vytex.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - SHARE-BASED COMPENSATION Sheet http://vytex.com/role/Share-basedCompensation SHARE-BASED COMPENSATION Notes 15 false false R16.htm 00000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://vytex.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 00000017 - Disclosure - BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://vytex.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesPolicies BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://vytex.com/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://vytex.com/role/IntangibleAssets 18 false false R19.htm 00000019 - Disclosure - NOTES PAYABLE AND LOAN FACILITY (Tables) Notes http://vytex.com/role/NotesPayableAndLoanFacilityTables NOTES PAYABLE AND LOAN FACILITY (Tables) Tables http://vytex.com/role/NotesPayableAndLoanFacility 19 false false R20.htm 00000020 - Disclosure - SHARE-BASED COMPENSATION (Tables) Sheet http://vytex.com/role/Share-basedCompensationTables SHARE-BASED COMPENSATION (Tables) Tables http://vytex.com/role/Share-basedCompensation 20 false false R21.htm 00000021 - Disclosure - BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://vytex.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesDetailsNarrative BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://vytex.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesPolicies 21 false false R22.htm 00000022 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative) Sheet http://vytex.com/role/LiquidityAndGoingConcernDetailsNarrative LIQUIDITY AND GOING CONCERN (Details Narrative) Details http://vytex.com/role/LiquidityAndGoingConcern 22 false false R23.htm 00000023 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative) Sheet http://vytex.com/role/DiscontinuedOperationsDetailsNarrative DISCONTINUED OPERATIONS (Details Narrative) Details http://vytex.com/role/DiscontinuedOperations 23 false false R24.htm 00000024 - Disclosure - INTANGIBLE ASSETS (Details) Sheet http://vytex.com/role/IntangibleAssetsDetails INTANGIBLE ASSETS (Details) Details http://vytex.com/role/IntangibleAssetsTables 24 false false R25.htm 00000025 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://vytex.com/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://vytex.com/role/IntangibleAssetsTables 25 false false R26.htm 00000026 - Disclosure - NOTES PAYABLE AND LOAN FACILITY (Details) Notes http://vytex.com/role/NotesPayableAndLoanFacilityDetails NOTES PAYABLE AND LOAN FACILITY (Details) Details http://vytex.com/role/NotesPayableAndLoanFacilityTables 26 false false R27.htm 00000027 - Disclosure - NOTES PAYABLE AND LOAN FACILITY (Details Narrative) Notes http://vytex.com/role/NotesPayableAndLoanFacilityDetailsNarrative NOTES PAYABLE AND LOAN FACILITY (Details Narrative) Details http://vytex.com/role/NotesPayableAndLoanFacilityTables 27 false false R28.htm 00000028 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://vytex.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://vytex.com/role/StockholdersEquity 28 false false R29.htm 00000029 - Disclosure - SHARE-BASED COMPENSATION (Details) Sheet http://vytex.com/role/Share-basedCompensationDetails SHARE-BASED COMPENSATION (Details) Details http://vytex.com/role/Share-basedCompensationTables 29 false false R30.htm 00000030 - Disclosure - SHARE-BASED COMPENSATION (Details 1) Sheet http://vytex.com/role/Share-basedCompensationDetails1 SHARE-BASED COMPENSATION (Details 1) Details http://vytex.com/role/Share-basedCompensationTables 30 false false R31.htm 00000031 - Disclosure - SHARE-BASED COMPENSATION (Details 2) Sheet http://vytex.com/role/Share-basedCompensationDetails2 SHARE-BASED COMPENSATION (Details 2) Details http://vytex.com/role/Share-basedCompensationTables 31 false false R32.htm 00000032 - Disclosure - SHARE-BASED COMPENSATION (Details Narrative) Sheet http://vytex.com/role/Share-basedCompensationDetailsNarrative SHARE-BASED COMPENSATION (Details Narrative) Details http://vytex.com/role/Share-basedCompensationTables 32 false false R33.htm 00000033 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://vytex.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://vytex.com/role/SubsequentEvents 33 false false All Reports Book All Reports vyst-20170930.xml vyst-20170930.xsd vyst-20170930_cal.xml vyst-20170930_def.xml vyst-20170930_lab.xml vyst-20170930_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 50 0001387131-17-005495-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-17-005495-xbrl.zip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
&UL4$L! A0#% @ HE1N2WJX MPI5.%0 )D@! !4 ( !O'$ '9Y,QJCX #9\ P 5 " M 3V' !V>7-T+3(P,3&UL4$L%!@ & 8 B@$ +M $! end